var title_f25_22_25952="Peritoneal dialysis PI";
var content_f25_22_25952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peritoneal dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows a person having peritoneal dialysis. The dialysis fluid (fresh dialysis solution) flows into the person's belly. It stays there for a certain amount of time, and then it drains out into the drain bag. The \"transfer set\" is the tubing that connects a thin tube (catheter) in the person's belly to the dialysis equipment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Treatment Methods for Kidney Failure: Peritoneal Dialysis. National Institute of Diabetes and Digestive and Kidney Diseases. Available at:",
"     <a href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/peritoneal\" target=\"_blank\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/peritoneal",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25952=[""].join("\n");
var outline_f25_22_25952=null;
var title_f25_22_25953="Uveitis PI";
var content_f25_22_25953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Uveitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Uveitis is inflammation of the uvea, which includes the iris, the cilliary body, and the choroid layer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25953=[""].join("\n");
var outline_f25_22_25953=null;
var title_f25_22_25954="Patient information: Minimally invasive surgery (The Basics)";
var content_f25_22_25954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16245\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/50/24353\">",
"         Thoracoscopic surgery",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/21/29010\">",
"          Laparoscopic surgery (gallbladder removal)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/21/42321\">",
"           Hysteroscopic surgery",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/52/27457\">",
"            Arthroscopic surgery",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"             Upper endoscopy",
"            </a>",
"            <li>",
"             <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"              Colonoscopy",
"             </a>",
"            </li>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/42/6818\">",
"         Patient information: Anesthesia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/48/19202\">",
"         Patient information: Endovascular surgery (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Minimally invasive surgery (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/minimally-invasive-surgery-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8509590\">",
"      <span class=\"h1\">",
"       What is minimally invasive surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Minimally invasive surgery is a type of surgery that uses special tools that are designed to decrease the size of incisions and reduce how much the body&rsquo;s tissues get damaged. One kind of minimally invasive surgery involves the use of a &ldquo;scope,&rdquo; a viewing device that allows surgeons to look inside the body without opening it up all the way. Another type, called &ldquo;endovascular surgery,&rdquo; uses X-rays to see inside the body while the surgeon uses special devices that fit inside the blood vessels. This article is about the type of surgery that involves scopes.",
"     </p>",
"     <p>",
"      There are several different types of scopes, but they all work in roughly the same way. They consist of a long, thin tube with a tiny camera and a light on the end. The camera sends pictures of the inside of the body to a TV screen. When doing this type of surgery, the surgeon makes a small incision just big enough for the scope to fit through. He or she also makes 2 or more other incisions that narrow tools can fit through. These tools include clamps, scissors, and stitching devices, which the surgeon can control from outside the body. While looking at the picture on the screen, the surgeon uses those tools to do the operation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8509597\">",
"      <span class=\"h1\">",
"       What are the different types of minimally invasive scope surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are lots of different types. Their names are based on the body parts that are involved. The scopes used for the different types of surgery are named that way, too:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Thoracoscopes",
"        </strong>",
"        are used in the chest for &ldquo;thoracoscopic surgery.&rdquo; (&ldquo;Thorax&rdquo; is the Greek word for chest.) This type of surgery can be used to remove pieces of lung or to do certain types of heart surgery (",
"        <a class=\"graphic graphic_figure graphicRef54182 \" href=\"UTD.htm?23/50/24353\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Laparoscopes",
"        </strong>",
"        are used in the belly for &ldquo;laparoscopic surgery.&rdquo; (&ldquo;Lapara&rdquo; is the Greek word for the space between the bottom of the rib cage and the hips.) This type of surgery can be used to remove the gallbladder or the uterus, or to do lots of other different procedures (",
"        <a class=\"graphic graphic_figure graphicRef56022 \" href=\"UTD.htm?28/21/29010\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Hysteroscopes",
"        </strong>",
"        are used in the uterus and vagina for &ldquo;hysteroscopic surgery.&rdquo; (&ldquo;Hystera\" is the Greek word for womb, or uterus.) This type of surgery can be used to remove abnormal growths in the uterus, or to do a number of different procedures on the uterus and vagina (",
"        <a class=\"graphic graphic_figure graphicRef75492 \" href=\"UTD.htm?41/21/42321\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Arthroscopes",
"        </strong>",
"        are used inside joints for &ldquo;arthroscopic surgery.&rdquo; (&ldquo;Arthron&rdquo; is the Greek word for joint.) This type of surgery can be used to repair or replace joints in the knee, shoulder, and hip (",
"        <a class=\"graphic graphic_figure graphicRef63687 \" href=\"UTD.htm?26/52/27457\">",
"         figure 4",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Endoscopes",
"        </strong>",
"        go down your throat and into the esophagus, stomach, or intestines (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"UTD.htm?36/39/37490\">",
"         figure 5",
"        </a>",
"        ). Sometimes these scopes are used for surgery. Other times they're used just to inspect those body parts. (&ldquo;Endo&rdquo; is the Greek root for inside or within.)",
"       </li>",
"       <li>",
"        <strong>",
"         Colonoscopes",
"        </strong>",
"        go up your rectum and into the large intestine, or colon. They are similar to endoscopes (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 6",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8509604\">",
"      <span class=\"h1\">",
"       How is minimally invasive surgery different from regular surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general&mdash;not always&mdash;this type of surgery makes recovery easier. That's because:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        It usually involves several small wounds, rather than one big one",
"       </li>",
"       <li>",
"        The inside of the body does not get as exposed to open air as it would with regular surgery",
"       </li>",
"       <li>",
"        The organs don't get moved around as much",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Despite all of the differences with regular surgery, minimally invasive surgery is still surgery. People who have it do have some pain, they do often need stitches, and they can develop infections or other problems because of the surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8509611\">",
"      <span class=\"h1\">",
"       Can patients always choose to have minimally invasive surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Many procedures can now be done through a minimally invasive approach. But it's not always up to the patient to choose what type of surgery to have. Whether or not a patient can have this type of surgery will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Whether there is a surgeon available who has enough experience doing the type of surgery the patient needs",
"       </li>",
"       <li>",
"        Why the patient needs surgery. (For example, patients who need surgery to remove very large cancers cannot always have minimally invasive procedures.)",
"       </li>",
"       <li>",
"        What other health problems the patient might have",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Even when a patient starts out having minimally invasive surgery, there's no guarantee that the surgery will stay that way. Sometimes surgeons start out doing minimally invasive surgery and then realize that they need to switch to open surgery. This doesn&rsquo;t mean the surgeon has done anything wrong; it's just something that happens sometimes after a surgery gets started.",
"     </p>",
"     <p>",
"      If you go in for minimally invasive surgery, be prepared to wake up and find out that you had open surgery. This could happen for a few different reasons, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The surgeon found something unexpected when he or she got started",
"       </li>",
"       <li>",
"        The surgeon couldn&rsquo;t see well enough or properly treat the organ he or she was trying to operate on",
"       </li>",
"       <li>",
"        Bleeding occurred that could not be controlled with a minimally invasive approach",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The important thing to remember is that if a surgeon switches to regular surgery, it is usually to protect the safety of the patient.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8509618\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=see_link\">",
"       Patient information: Anesthesia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/48/19202?source=see_link\">",
"       Patient information: Endovascular surgery (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/22/25954?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16245 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25954=[""].join("\n");
var outline_f25_22_25954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8509590\">",
"      What is minimally invasive surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8509597\">",
"      What are the different types of minimally invasive scope surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8509604\">",
"      How is minimally invasive surgery different from regular surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8509611\">",
"      Can patients always choose to have minimally invasive surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8509618\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/50/24353\">",
"      Thoracoscopic surgery",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/21/29010\">",
"       Laparoscopic surgery (gallbladder removal)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/21/42321\">",
"        Hysteroscopic surgery",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/52/27457\">",
"         Arthroscopic surgery",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"          Upper endoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"           Colonoscopy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=related_link\">",
"      Patient information: Anesthesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/48/19202?source=related_link\">",
"      Patient information: Endovascular surgery (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_22_25955="Blocked sinus passage 1 PI";
var content_f25_22_25955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Blocked sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts a woman with chronic rhinosinusitis. The sinus becomes swollen, blocking the passage and leading to mucus buildup.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25955=[""].join("\n");
var outline_f25_22_25955=null;
var title_f25_22_25956="Instruments nail surgery";
var content_f25_22_25956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Instruments for nail surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25956=[""].join("\n");
var outline_f25_22_25956=null;
var title_f25_22_25957="Nortriptyline: Patient drug information";
var content_f25_22_25957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nortriptyline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     see \"Nortriptyline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/26/38310?source=see_link\">",
"     see \"Nortriptyline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pamelor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nortriptyline&reg;;",
"     </li>",
"     <li>",
"      Ava-Nortriptyline;",
"     </li>",
"     <li>",
"      Aventyl&reg;;",
"     </li>",
"     <li>",
"      Dom-Nortriptyline;",
"     </li>",
"     <li>",
"      Norventyl;",
"     </li>",
"     <li>",
"      Nu-Nortriptyline;",
"     </li>",
"     <li>",
"      PMS-Nortriptyline;",
"     </li>",
"     <li>",
"      Teva-Nortriptyline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nicotine withdrawal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nortriptyline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10917 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25957=[""].join("\n");
var outline_f25_22_25957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030838\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030840\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030839\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030844\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030845\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030847\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030842\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030843\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030848\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030849\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=related_link\">",
"      Nortriptyline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/26/38310?source=related_link\">",
"      Nortriptyline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_22_25958="Nitrofurantoin: Drug information";
var content_f25_22_25958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitrofurantoin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14421?source=see_link\">",
"    see \"Nitrofurantoin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/21/10581?source=see_link\">",
"    see \"Nitrofurantoin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Furadantin&reg;;",
"     </li>",
"     <li>",
"      Macrobid&reg;;",
"     </li>",
"     <li>",
"      Macrodantin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nitrofurantoin&reg;;",
"     </li>",
"     <li>",
"      Macrobid&reg;;",
"     </li>",
"     <li>",
"      Macrodantin&reg;;",
"     </li>",
"     <li>",
"      Novo-Furantoin;",
"     </li>",
"     <li>",
"      Teva-Nitrofurantoin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      UTI treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Furadantin&reg;, Macrodantin&reg;: Oral: 50-100 mg/dose every 6 hours; administer for 7 days or at least 3 days after obtaining sterile urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Macrobid&reg;: Oral: 100 mg twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      UTI prophylaxis",
"     </b>",
"     (Furadantin&reg;, Macrodantin&reg;): Oral: 50-100 mg/dose at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F202031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/21/10581?source=see_link\">",
"      see \"Nitrofurantoin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      UTI treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &gt;1 month",
"     </i>",
"     (Furadantin&reg;, Macrodantin&reg;): Oral:  5-7 mg/kg/day in divided doses every 6 hours (maximum: 400 mg/day). Administer for 7 days or at least 3 days after obtaining sterile urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &gt;12 years",
"     </i>",
"     (Macrobid&reg;): Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      UTI prophylaxis:",
"     </b>",
"     Children &gt;1 month (Furadantin&reg;, Macrodantin&reg;): Oral: 1-2 mg/kg/day in divided doses every 12-24 hours (maximum: 100 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use; alternative agents preferred. Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F202014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Contraindicated in hemo- and peritoneal dialysis and continuous arteriovenous or venovenous hemofiltration.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [macrocrystal]: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Macrodantin&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [macrocrystal/monohydrate]: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Macrobid&reg;: 100 mg [nitrofurantoin macrocrystal 25% and nitrofurantoin monohydrate 75%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 25 mg/5 mL (230 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Furadantin&reg;: 25 mg/5 mL (230 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals to improve absorption and decrease adverse effects; suspension may be mixed with water, milk, fruit juice, or infant formula. Shake suspension well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of urinary tract infections caused by susceptible strains of",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      S. aureus, Enterococcus, Klebsiella,",
"     </i>",
"     and",
"     <i>",
"      Enterobacter",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3245417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound alike/look alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Macrobid&reg; may be confused with microK&reg;, Nitro-Bid&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitrofurantoin may be confused with Neurontin&reg;, nitroglycerin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cyanosis, ECG changes (nonspecific ST/T wave changes, bundle branch block)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bulging fontanels (infants), chills, confusion, depression, dizziness, drowsiness, fever, headache, malaise, pseudotumor cerebri, psychotic reaction, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, erythema multiforme, exfoliative dermatitis, pruritus, rash (eczematous, erythematous, maculopapular), Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperphosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia,",
"     <i>",
"      C. difficile",
"     </i>",
"     colitis, constipation, diarrhea, dyspepsia, flatulence, nausea, pancreatitis, pseudomembranous colitis, sialadenitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine discoloration (brown)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, glucose-6-phosphate dehydrogenase deficiency anemia, granulocytopenia, hemoglobin decreased, hemolytic anemia, leukopenia, megaloblastic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis, hepatic necrosis, transaminases increased, jaundice (cholestatic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, numbness, paresthesia, peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, nystagmus, optic neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonitis, pulmonary fibrosis (with long-term use), pulmonary infiltration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Acute pulmonary reaction (symptoms include chills, chest pain, cough, dyspnea, fever, and eosinophilia), anaphylaxis, hypersensitivity (including acute pulmonary hypersensitivity), lupus-like syndrome, superinfections (eg,",
"     <i>",
"      Pseudomonas",
"     </i>",
"     or",
"     <i>",
"      Candida",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitrofurantoin or any component of the formulation; significant renal impairment (anuria, oliguria, significantly elevated serum creatinine, or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute); infants &lt;1 month (due to the possibility of hemolytic anemia); pregnancy at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent; use in patients with a history of cholestatic jaundice or hepatic impairment with previous nitrofurantoin therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic reactions: Rare, but severe and sometimes fatal hepatic reactions (eg, cholestatic jaundice, hepatitis, hepatic necrosis) have been associated with use (onset may be insidious); discontinue immediately if hepatitis occurs. Monitor liver function tests periodically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Has been associated with peripheral neuropathy (rare); risk may be increased in patients with anemia, renal impairment, diabetes, vitamin B deficiency, debilitating disease, or electrolyte imbalance; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity:  Acute, subacute, or chronic (usually after 6 months of therapy) pulmonary reactions (possibly fatal) have been observed; if these occur, discontinue therapy immediately. Monitor closely for malaise, dyspnea, cough, fever, radiologic evidence of diffuse interstitial pneumonitis or fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Use caution in patients with G6PD deficiency; may be at increased risk for hemolytic anemia. Discontinue therapy if occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Therapeutic concentrations are not attained in urine of patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute, therefore, use is contraindicated in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use for  long-term suppression  or in patients with decreased renal function (contraindicated in Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute) due to potential for pulmonary toxicity and availability of safer alternative agents (Beers Criteria). Use in the elderly, particularly females receiving long-term prophylaxis for recurrent UTIs, has also been associated with an increased risk of hepatic toxicity and peripheral neuropathy. Monitor closely for toxicities during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use is contraindicated in children &lt;1 month of age (at increased risk for hemolytic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Pyelonephritis: Not indicated for the treatment of pyelonephritis or perinephric abscesses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nitrofurantoin may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Trisilicate: May decrease the serum concentration of Nitrofurantoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norfloxacin: Nitrofurantoin may diminish the therapeutic effect of Norfloxacin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nitrofurantoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: Nitrofurantoin may enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F202002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Nitrofurantoin serum concentrations may be increased if taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (contraindicated at term) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects have not been observed in animals, nitrofurantoin is classified pregnancy category B. Nitrofurantoin crosses the placenta, but very little reaches the amniotic fluid. Most published experiences with nitrofurantoin use during pregnancy have failed to identify any increased obstetric or teratogenic risks. Isolated reports of a potential increased risk for cardiovascular defects and a case report of upper limb paralysis have not been replicated in other studies. Use of nitrofurantoin during pregnancy has been generally well tolerated with rare reports of maternal toxicity including severe pulmonary reactions or hematologic adverse effects. Nitrofurantoin is contraindicated in pregnant patients at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent due to the possibility of hemolytic anemia in the neonate.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F202018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (infants &lt;1 month); AAP rates &ldquo;compatible&rdquo; (AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F201992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minimal, if any, nitrofurantoin distributes to human milk. Use of nitrofurantoin during breast-feeding is not recommended by the manufacturer. Use with caution in patients at risk for G6PD deficiency or in newborns at risk for hyperbilirubinemia. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7285895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals to improve absorption and decrease adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Macrobid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $427.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Macrodantin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $240.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $252.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $391.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nitrofurantoin Macrocrystal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $199.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $338.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nitrofurantoin Monohyd Macro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $320.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Furadantin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (230 mL): $975.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Nitrofurantoin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (230 mL): $608.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F201979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of pulmonary reaction; signs of numbness or tingling of the extremities; CBC, periodic liver function tests, periodic renal function tests with long-term use",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chemiofurin (ES);",
"     </li>",
"     <li>",
"      Furadantin (AT, IN, NO, SE);",
"     </li>",
"     <li>",
"      Furadantin Retard (CH);",
"     </li>",
"     <li>",
"      Furadantina (AR, MX);",
"     </li>",
"     <li>",
"      Furadantine (FR, LU);",
"     </li>",
"     <li>",
"      Furadantine MC (BE);",
"     </li>",
"     <li>",
"      Furadantine-MC (NL, PT);",
"     </li>",
"     <li>",
"      Furadin (PK);",
"     </li>",
"     <li>",
"      Furadina (VE);",
"     </li>",
"     <li>",
"      Furanpur (UY);",
"     </li>",
"     <li>",
"      Furantoina (ES);",
"     </li>",
"     <li>",
"      Furobactina (ES);",
"     </li>",
"     <li>",
"      Furolin (GR);",
"     </li>",
"     <li>",
"      Macrobid (GB, IE);",
"     </li>",
"     <li>",
"      Macrodantin (AU, GB, IL, IT, PH, ZA);",
"     </li>",
"     <li>",
"      Macrodantina (BR, CN, CO, CR, DO, GT, HN, MX, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Macrodin (CY);",
"     </li>",
"     <li>",
"      Macrofuran (ID);",
"     </li>",
"     <li>",
"      Micturol Simple (ES);",
"     </li>",
"     <li>",
"      Nifuran (NZ);",
"     </li>",
"     <li>",
"      Nifurantin (CZ);",
"     </li>",
"     <li>",
"      Nifuryl (EC);",
"     </li>",
"     <li>",
"      Nitrofurantoin &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Nitrofurantoin-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Orafuran (BG);",
"     </li>",
"     <li>",
"      Piyeloseptyl (TR);",
"     </li>",
"     <li>",
"      Siraliden (PL);",
"     </li>",
"     <li>",
"      Tanding (CL);",
"     </li>",
"     <li>",
"      Urantoin (EC);",
"     </li>",
"     <li>",
"      Uro-Tablinen (DE);",
"     </li>",
"     <li>",
"      Urofuran (FI);",
"     </li>",
"     <li>",
"      Urotoina (PY);",
"     </li>",
"     <li>",
"      Uvamin (IL);",
"     </li>",
"     <li>",
"      Uvamin Retard (CH, GT, HN, NI, PA, SV, TT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits several bacterial enzyme systems including acetyl coenzyme A interfering with metabolism and possibly cell wall synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; macrocrystalline form absorbed more slowly due to slower dissolution (causes less GI distress)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Body tissues (except plasma) metabolize 60% of drug to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Increased with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-60 minutes; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: Urine (~40%) and feces (small amounts) as metabolites and unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Macrocrystals: Urine (20% to 25% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhullar S, Lele SM, and Kraman S, &ldquo;Severe Nitrofurantoin Lung Disease Resolving Without the Use of Steroids,&rdquo;",
"      <i>",
"       J Postgrad Med",
"      </i>",
"      , 2007, 53(2):111-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/17495377/pubmed\" id=\"17495377\" target=\"_blank\">",
"        17495377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brendstrup L, Hjelt K, Petersen KE, et al, &ldquo;Nitrofurantoin Versus Trimethoprim Prophylaxis in Recurrent Urinary Tract Infections in Children,&rdquo;",
"      <i>",
"       Acta Paediatr Scand",
"      </i>",
"      , 1990. 79(12):1225-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/2085111/pubmed\" id=\"2085111\" target=\"_blank\">",
"        2085111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burgert SJ, Burke JP, and Box TD, &ldquo;Reversible Nitrofurantoin-Induced Chronic Active Hepatitis and Hepatic Cirrhosis in a Patient Awaiting Liver Transplantation,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(3):448-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/7871583/pubmed\" id=\"7871583\" target=\"_blank\">",
"        7871583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coraggio MJ, Gross TP, and Roscelli JD, &ldquo;Nitrofurantoin Toxicity in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(3):163-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/2652087/pubmed\" id=\"2652087\" target=\"_blank\">",
"        2652087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      D'Arcy PF, &ldquo;Nitrofurantoin,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1985, 19(7-8):540-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/3896715/pubmed\" id=\"3896715\" target=\"_blank\">",
"        3896715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kammire LD and Donofrio PD, &ldquo;Nitrofurantoin Neuropathy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(2 Pt 2):510-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/17666646/pubmed\" id=\"17666646\" target=\"_blank\">",
"        17666646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly BD, Heneghan MA, Bennani F, et al, &ldquo;Nitrofurantoin-Induced Hepatotoxicity Mediated by CD8+ T Cells,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1998, 93(5):819-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/9625135/pubmed\" id=\"9625135\" target=\"_blank\">",
"        9625135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Penn RG and Griffin HP, &ldquo;Adverse Reactions to Nitrofurantoin in the United Kingdom, Sweden, and Holland,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1982, 284(6327):1440-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Practice Parameter: The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants and Young Children. American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4 Pt 1):843-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/10103321/pubmed\" id=\"10103321\" target=\"_blank\">",
"        10103321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson C and Nyi PP, &ldquo;Probable Nitrofurantoin-Induced Bronchiolitis Obliterans With Organizing Pneumonia,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2009, 66(21):1919-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/19850785/pubmed\" id=\"19850785\" target=\"_blank\">",
"        19850785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams EM and Triller DM, &ldquo;Recurrent Acute Nitrofurantoin-Induced Pulmonary Toxicity,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(5):713-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25958/abstract-text/16718946/pubmed\" id=\"16718946\" target=\"_blank\">",
"        16718946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9704 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-EC95FD50DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25958=[""].join("\n");
var outline_f25_22_25958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202007\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202008\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202050\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202012\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202031\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202013\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202014\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201981\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201965\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201985\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201984\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3245417\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202048\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201988\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201969\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299767\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201974\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202002\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201977\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201991\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202018\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201992\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7285895\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201990\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201979\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201993\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201968\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201987\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14421?source=related_link\">",
"      Nitrofurantoin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/21/10581?source=related_link\">",
"      Nitrofurantoin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_22_25959="Lorazepam: Pediatric drug information";
var content_f25_22_25959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lorazepam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"    see \"Lorazepam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/13/19669?source=see_link\">",
"    see \"Lorazepam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ativan&reg;;",
"     </li>",
"     <li>",
"      Lorazepam Intensol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lorazepam&reg;;",
"     </li>",
"     <li>",
"      Ativan&reg;;",
"     </li>",
"     <li>",
"      Dom-Lorazepam;",
"     </li>",
"     <li>",
"      Lorazepam Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Lorazem;",
"     </li>",
"     <li>",
"      Nu-Loraz;",
"     </li>",
"     <li>",
"      PHL-Lorazepam;",
"     </li>",
"     <li>",
"      PMS-Lorazepam;",
"     </li>",
"     <li>",
"      PRO-Lorazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianxiety Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Status epilepticus: I.V.: 0.05 mg/kg slow I.V. over 2-5 minutes; may repeat in 10-15 minutes (see warning regarding benzyl alcohol)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"      see \"Lorazepam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjunct to antiemetic therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: I.V.: Limited information exists in the literature, especially for multiple doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single dose: 0.04-0.08 mg/kg/dose prior to chemotherapy (maximum dose: 4 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Multiple doses: Some centers use 0.02-0.05 mg/kg/dose (maximum dose: 2 mg) every 6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral, I.V.: 0.5-2 mg every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anxiety/sedation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: Oral, I.V.: Usual: 0.05 mg/kg/dose (maximum dose: 2 mg/dose) every 4-8 hours; range: 0.02-0.1 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral: 1-10 mg/day in 2-3 divided doses; usual dose: 2-6 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Insomnia: Adults: Oral: 2-4 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Operative amnesia: Adults: I.V.: Up to 0.05 mg/kg; maximum dose: 4 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preoperative: Adults: I.M.: 0.05 mg/kg administered 2 hours before surgery; maximum dose: 4 mg/dose; I.V.: 0.044 mg/kg 15-20 minutes before surgery; usual maximum dose: 2 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sedation (preprocedure): Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M., I.V.: Usual: 0.05 mg/kg; range: 0.02-0.09 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: May use smaller doses (eg, 0.01-0.03 mg/kg) and repeat every 20 minutes, as needed to titrate to effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Status epilepticus: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 0.05-0.1 mg/kg (maximum: 4 mg/dose) slow I.V. over 2-5 minutes (maximum rate: 2 mg/minute); may repeat every 10-15 minutes if needed (Hegenbarth, 2008; Sabo-Graham, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 0.07 mg/kg (maximum: 4 mg/dose) slow I.V. over 2-5 minutes (maximum rate: 2 mg/minute); may repeat in 10-15 minutes if needed; usual total maximum dose: 8 mg (Crawford, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 4 mg/dose slow I.V. over 2-5 minutes (maximum rate: 2 mg/minute); may repeat in 10-15 minutes; usual total maximum dose: 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     I.V.: Risk of propylene glycol toxicity. Monitor closely if using for prolonged periods of time or at high doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Use with caution; benzodiazepines may worsen hepatic encephalopathy; decrease dosage in patients with severe hepatic insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ativan&reg;: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol 400, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]: 2 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lorazepam Intensol&trade;: 2 mg/mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ativan&reg;: 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ativan&reg;: 1 mg, 2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F189975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food to decrease GI distress; dilute oral solution in water, juice, soda, or semisolid food (eg, applesauce, pudding). Single oral doses &gt;0.09 mg/kg produced increased ataxia without increasing sedative benefit vs lower doses. Since both strengths of injection contain 2% benzyl alcohol, some experts recommend using the 4 mg/mL strength for dilution with",
"     <b>",
"      preservative free",
"     </b>",
"     SWI to make a 0.4 mg/mL dilution for I.V. use in neonates (in order to decrease the amount of benzyl alcohol delivered to the neonate); however, the stability of this dilution has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Do not exceed 2 mg/minute or 0.05 mg/kg over 2-5 minutes; dilute I.V. dose with equal volume of compatible diluent (D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, SWI); administer I.V. using repeated aspiration with slow I.V. injection, to make sure the injection is not intra-arterial and that perivascular extravasation has not occurred",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Administer undiluted by deep injection into muscle mass",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F189981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, albumin, allopurinol, amifostine, amikacin, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, anakinra, atracurium, bivalirudin, bumetanide, caspofungin, cefepime, cefotaxime, ciprofloxacin, cisatracurium, cisplatin, cladribine, clonidine, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, epinephrine, erythromycin lactobionate, etomidate, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, fosphenytoin, furosemide, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, labetalol, levofloxacin, linezolid, melphalan, methadone, methotrexate, metronidazole, micafungin, midazolam, milrinone, morphine, nicardipine, nitroglycerin, norepinephrine, oxaliplatin, paclitaxel, palonosetron, pancuronium, pemetrexed, piperacillin, piperacillin/tazobactam, potassium chloride, ranitidine, remifentanil, sulfamethoxazole/trimethoprim, tacrolimus, teniposide, thiotepa, vancomycin, vecuronium, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, aztreonam, caffeine citrate, floxacillin, gallium nitrate, idarubicin, imipenem/cilastatin, ondansetron, pantoprazole, sargramostim, sufentanil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Foscarnet, propofol, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aripiprazole, cimetidine, dimenhydrinate, haloperidol, hydromorphone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, pantoprazole, sufentanil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Store intact vials in the refrigerator; room temperature storage information may be available; contact product manufacturer to obtain current recommendations; protect from light. Do not use if injection is discolored or contains precipitate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); dispense only in the bottle and with the calibrated dropper provided. Discard open bottle after 90 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of anxiety; status epilepticus; preoperative sedation and amnesia; adjunct to antiemetic therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       LORazepam may be confused with ALPRAZolam, clonazePAM, diazepam, KlonoPIN&reg;, Lovaza&reg;, temazepam, zolpidem",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Ativan&reg; may be confused with Ambien&reg;, Atarax&reg;, Atgam&reg;, Avitene&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Injection dosage form contains propylene glycol. Monitor for toxicity when administering continuous lorazepam infusions.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F189980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Akathisia, amnesia confusion, ataxia, disinhibition, depression, disorientation, dizziness, euphoria, headache, sedation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Changes in appetite, nausea, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, hyperventilation, nasal congestion, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening:  Asthenia, blood dyscrasias, disinhibition, euphoria, fatigue, increased salivation, menstrual irregularities, physical and psychological dependence (with prolonged use), reflex slowing, polyethylene glycol or propylene glycol poisoning (prolonged I.V. infusion), suicidal ideation, seizure, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lorazepam or any component; there may be a cross-sensitivity with other benzodiazepines; do not use in a comatose patient, those with pre-existing CNS depression, narrow-angle glaucoma, severe uncontrolled pain, severe hypotension",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in neonates, especially in preterm infants; several cases of neurotoxicity and myoclonus (rhythmic myoclonic jerking) have been reported. Use with caution in patients with renal or hepatic impairment; benzodiazepines may worsen hepatic encephalopathy; decrease dosage in patients with severe hepatic insufficiency. Use with caution in patients with compromised pulmonary function (including those with COPD or sleep apnea), CNS depression, or those receiving other CNS depressants. Debilitated patients may be more susceptible to the sedative effects of benzodiazepines; monitor closely; titrate dosage carefully according to patient response.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Benzodiazepines have been associated with anterograde amnesia; they do not have analgesic, antidepressant, or antipsychotic properties. Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in pediatric/adolescent or psychiatric patients; discontinue drug if this occurs. As a hypnotic, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and require immediate and careful evaluation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Safety and efficacy of long-term use (&gt;4 months) have not been established; long-term usefulness should be periodically re-evaluated for the individual patient. Safety and efficacy of oral lorazepam in children &lt;12 years and safety of injectable lorazepam in children &lt;18 years have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzodiazepines may cause significant and potentially fatal respiratory depression, both if used alone and if used in combination with other CNS depressants. May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May cause emergent or worsening of pre-existing depression; not recommended for use in patients with a primary depressive disorder or psychosis, particularly if suicidal risk may be present; do not use without adequate antidepressant therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause physical and psychological dependence with prolonged use; do not abruptly discontinue; rebound or withdrawal symptoms (including seizures) may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause acute withdrawal in patients receiving long-term benzodiazepine therapy. Potential for drug dependency exists; use benzodiazepines with caution in patients with a history of drug abuse, alcoholism, or significant personality disorders; risk of dependence increases with higher dosage and longer duration of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Dilute injection prior to I.V. use",
"     </b>",
"     with equal volume of compatible diluent (D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, SWI); do not inject intra-arterially, arteriospasm and gangrene may occur. Injection contains 2% benzyl alcohol and polyethylene glycol, which may be toxic to newborns in high doses; benzyl alcohol may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use lorazepam products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concentrated oral solution and injection contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use lorazepam products containing propylene glycol with caution in neonates. Concentrated oral solution contains polyethylene glycol which may have adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loxapine: May enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some animal studies. Lorazepam and its metabolite cross the human placenta. Teratogenic effects in humans have been observed with some benzodiazepines (including lorazepam); however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines (including lorazepam). Elimination of lorazepam in the newborn infant is slow; following",
"     <i>",
"      in utero",
"     </i>",
"     exposure, term infants may excrete lorazepam for up to 8 days.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, blood pressure, heart rate; CBC with differential and liver function with long-term use",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA, which is a major inhibitory neurotransmitter in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Within 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, I.M.: Rapid, complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses into placenta; crosses into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 0.76 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 1.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily by glucuronide conjugation in the liver to an inactive metabolite (lorazepam glucuronide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 90% to 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Full-term neonates: 40.2 hours; range: 18-73 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Older Children: 10.5 hours; range: 6-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 12.9 hours; range: 10-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine primarily as the glucuronide conjugate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: Lorazepam: Poorly dialyzable; lorazepam glucuronide: May be highly dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/13/19669?source=see_link\">",
"      see \"Lorazepam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine; may be habit-forming; avoid abrupt discontinuation after prolonged use; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diarrhea in a 9-month old infant receiving high-dose oral lorazepam was attributed to the lorazepam oral solution that contains polyethylene glycol and propylene glycol (both are osmotically active); diarrhea resolved when crushed tablets were substituted for the oral solution (Marshall, 1995). To avoid the adverse effects of polyethylene glycol and propylene glycol that are found in the commercially available oral solution, a 1 mg/mL oral suspension can also be made from tablets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lorazepam crosses the placenta. Neonatal withdrawal symptoms (or symptoms of toxicity) may occur in infants of mothers who receive benzodiazepines during the late phase of pregnancy or at delivery. Reported symptoms include: Hypoactivity, hypotonia, feeding problems, respiratory depression, apnea, hypothermia, and impaired metabolic response to cold stress. Lorazepam enters breast milk. Sedation, irritability, and inability to suckle may occur in infants exposed to lorazepam from breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11446285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (2 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Two different 1 mg/mL oral suspensions may be made from different generic lorazepam tablets (Mylan Pharmaceuticals or Watson Laboratories), sterile water, Ora-Sweet&reg;, and Ora-Plus&reg;.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">",
"     Mylan tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 144 mL of sterile water to disperse the tablets; shake until slurry is formed. Add 108 mL Ora-Plus&reg; in incremental proportions; then add a quantity of Ora-Sweet&reg; sufficient to make 360 mL. Label \"shake well\" and \"refrigerate\". Stable for 91 days when stored in amber glass prescription bottles at room temperature or refrigerated (preferred).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">",
"     Watson tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 48 mL sterile water to disperse the tablets; shake until slurry is formed. Add 156 mL of Ora-Plus&reg; in incremental proportions; then add a quantity of Ora-Sweet&reg; sufficient to make 360 mL. Label \"shake well\" and \"refrigerate\". Store in amber glass prescription bottles. Stable for 63 days at room temperature or 91 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Lee ME, Lugo RA, Rusho WJ, et al, \"Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures,\"",
"     <i>",
"      J Pediatr Pharmacol Ther",
"     </i>",
"     , 2004, 9(4):254-58.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatr",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crawford TO, Mitchell WG, and Snodgrass SR, &ldquo;Lorazepam in Childhood Status Epilepticus and Serial Seizures: Effectiveness and Tachyphylaxis,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1987, 37(2):190-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/3808299 /pubmed\" id=\"3808299 \" target=\"_blank\">",
"        3808299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deshmukh A, Wittert W, Schnitzler E, et al, &ldquo;Lorazepam in the Treatment of Refractory Neonatal Seizures: A Pilot Study,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1986, 140(10):1042-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/ 3752014 /pubmed\" id=\" 3752014 \" target=\"_blank\">",
"        3752014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henry DW, Burwinkle JW, and Klutman NE, &ldquo;Determination of Sedative and Amnestic Doses of Lorazepam in Children,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1991, 10(8):625-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/1934919/pubmed\" id=\"1934919\" target=\"_blank\">",
"        1934919",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee DS, Wong HA, and Knoppert DC, &ldquo;Myoclonus Associated With Lorazepam Therapy in Very-Low-Birth-Weight Infants,&rdquo;",
"      <i>",
"       Biol Neonate",
"      </i>",
"      , 1994, 66(6):311-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/7727612/pubmed\" id=\"7727612\" target=\"_blank\">",
"        7727612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall JD, Farrar HC, and Kearns GL, &ldquo;Diarrhea Associated With Enteral Benzodiazepine Solutions,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(4):657-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/7699551/pubmed\" id=\"7699551\" target=\"_blank\">",
"        7699551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDermott CA, Kowalczyk AL, Schnitzler ER, et al, &ldquo;Pharmacokinetics of Lorazepam in Critically Ill Neonates With Seizures,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(3):479-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/1538303/pubmed\" id=\"1538303\" target=\"_blank\">",
"        1538303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabo-Graham T and Seay AR, \"Management of Status Epilepticus in Children,\"",
"      <i>",
"       Pediatr Rev",
"      </i>",
"      , 1998, 19(9):306-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/22/25959/abstract-text/9745313/pubmed\" id=\"9745313\" target=\"_blank\">",
"        9745313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12565 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25959=[""].join("\n");
var outline_f25_22_25959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189926\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189927\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053736\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443858\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053729\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189896\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189880\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189975\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053741\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189981\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053732\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053740\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189983\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189980\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053745\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053728\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053727\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299616\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189889\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189891\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189908\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053735\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053726\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053743\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053744\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053734\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053746\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11446285\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12565|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=related_link\">",
"      Lorazepam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/13/19669?source=related_link\">",
"      Lorazepam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_22_25960="Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease";
var content_f25_22_25960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25960/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25960/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25960/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25960/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/22/25960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GVHD has been classically divided into acute and chronic disease based upon the time of onset:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute GVHD &mdash; disease presenting within the first 100 days of hematopoietic cell transplantation (HCT)",
"     </li>",
"     <li>",
"      Chronic GVHD &mdash; onset of disease after the first 100 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, this division at day 100 post-HCT is artificial and there has been a shift towards defining acute and chronic GVHD based upon the clinical manifestations of these diseases, rather than the arbitrary cut-off of a particular date post-transplantation. For unclear cases, the NIH consensus diagnostic criteria for GVHD includes an overlap syndrome in which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acute GVHD commonly demonstrate a classic maculopapular rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration. In contrast, patients with chronic GVHD have skin involvement resembling lichen planus or the cutaneous manifestations of scleroderma, dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract, and a rising serum bilirubin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinically significant acute GVHD occurs in patients who receive an allogeneic HCT despite intensive prophylaxis with immunosuppressive agents. Development of moderate (grade II) or severe (grade III or IV) acute GVHD after HCT is associated with a significant decrease in survival. Furthermore, once acute GVHD occurs, it may not be reversible.",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical manifestations and diagnosis of acute GVHD. Recommendations for the prevention and treatment of this disorder, as well as the clinical manifestations and treatment of chronic GVHD, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25782620\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant acute graft-versus-host disease (GVHD) occurs in 9 to 50 percent of patients who receive an allogeneic hematopoietic cell transplant (HCT) from a genotypically HLA-identical sibling, despite intensive prophylaxis with immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , corticosteroids, or antithymocyte globulin.",
"   </p>",
"   <p>",
"    Acute GVHD is also common in matched unrelated donors and in haploidentical related donors. A more detailed discussion of the various types of HCT and risk factors for development of acute GVHD is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have identified the following risk factors for the development of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Degree of HLA disparity (HLA mismatch or unrelated donor)",
"     </li>",
"     <li>",
"      Donor and recipient gender disparity (female donor to male recipient)",
"     </li>",
"     <li>",
"      Intensity of the transplant conditioning regimen",
"     </li>",
"     <li>",
"      Acute GVHD prophylactic regimen used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less well established risk factors include increasing age of the host, the cytomegalovirus (CMV) status of the donor and host, peripheral blood stem cell versus bone marrow transplantation, the presence of a sterile environment (including gut decontamination), and particular HLA haplotype. However, risk factors for acute GVHD differ by disease, requiring distinct risk models for each condition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report from the Center for International Blood and Marrow Transplant Research (CIBMTR), 5561 patients receiving an allogeneic hematopoietic cell transplantation from an HLA-identical sibling donor (3191 patient) or an unrelated donor (2370 patients) evaluated the role of the conditioning regimen and stem cell source on the cumulative incidence of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/4\">",
"     4",
"    </a>",
"    ]. After a median follow-up of approximately 40 months, the cumulative incidence rates of grade B or greater acute GVHD were 39 and 59 percent among patients receiving sibling donor or unrelated donor transplants, respectively. When analyzed according to the type of donor (sibling versus unrelated), the incidence of acute GVHD was significantly lower among patients treated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A myeloablative, non-total body irradiation (TBI)-containing conditioning regimen who received a bone marrow graft from a sibling (odds ratio [OR] 0.56; 95% CI 0.44-0.71).",
"     </li>",
"     <li>",
"      A reduced intensity conditioning (RIC) regimen who received peripheral blood progenitor cells from a sibling (OR 0.70; 95% CI 0.56-0.88).",
"     </li>",
"     <li>",
"      A myeloablative conditioning regimen without TBI who received a bone marrow graft from an unrelated donor (OR 0.55; 95% CI 0.40-0.75).",
"     </li>",
"     <li>",
"      A RIC regimen who received bone marrow or peripheral blood progenitor cells from an unrelated donor (OR 0.47; 95% CI 0.29-0.76).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the conditioning regimen of choice is often dictated by the underlying disorder, these results suggest that the source of donor stem cells (bone marrow versus peripheral blood) may be selected in the context of the planned conditioning regimen to minimize acute GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL AND HISTOLOGICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin, liver, gastrointestinal tract, and the hematopoietic system are the principal target organs in patients with acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, the first (and most common) clinical manifestation of acute GVHD is a maculopapular rash, usually occurring at or near the time of the white blood cell engraftment (",
"    <a class=\"graphic graphic_picture graphicRef74788 \" href=\"UTD.htm?40/28/41409\">",
"     picture 1",
"    </a>",
"    ). The rash initially involves the nape of the neck, ears, shoulders, the palms of the hands, and the soles of the feet. It can be described as a sunburn and may be pruritic or painful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=see_link\">",
"     \"Cutaneous manifestations of graft-versus-host disease (GVHD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From these initial areas of presentation, the rash may spread to involve the whole integument, eventually becoming confluent. In severe GVHD, the maculopapular rash forms bullous lesions with toxic epidermal necrolysis. The progression of GVHD can be clinically defined into four stages depending upon the extent of involvement of the skin and other organs and performance status (",
"    <a class=\"graphic graphic_table graphicRef68233 \" href=\"UTD.htm?8/63/9212\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82692 \" href=\"UTD.htm?42/15/43260\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Histologic examination of acute GVHD of the skin reveals changes in the dermal and epidermal layers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Characteristic findings include exocytosed lymphocytes, dyskeratotic epidermal keratinocytes, follicular involvement, satellite lymphocytes adjacent to or surrounding dyskeratotic epidermal keratinocytes, and dermal perivascular lymphocytic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/8\">",
"     8",
"    </a>",
"    ]. The most consistent histologic feature is individual cell death (apoptosis) at the base of crypts (",
"    <a class=\"graphic graphic_picture graphicRef54631 \" href=\"UTD.htm?23/4/23620\">",
"     picture 2",
"    </a>",
"    ). However, similar changes can result from cytotoxic therapy used in the preparative regimen for hematopoietic cell transplantation (HCT), and bacterial or viral infections or reactivations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We retrospectively reviewed 179 skin biopsies from 137 patients who had undergone allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/7\">",
"     7",
"    </a>",
"    ]. We also compared 98 skin biopsies from 71 patients with acute GVHD with 81 biopsies from 66 patients who underwent biopsy to exclude GVHD but did not go on to develop the disease on clinical grounds. A search for factors that separated GVHD biopsies from non-GVHD biopsies using logistic regression failed to reveal a single best predictor or combination of predictors, and no single parameter achieved statistical significance on univariate analysis. Therefore, while skin biopsies, when positive, are useful for the diagnosis of GVHD, they have limited predictive ability to determine which patients will go on to develop grade II or higher acute GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the second most commonly involved organ in acute GVHD. Rarely, patients have moderate to severe hepatic GVHD without evidence of cutaneous disease.",
"   </p>",
"   <p>",
"    Hepatic involvement is manifested by abnormal liver function tests, with the earliest and most common finding being a rise in the serum levels of conjugated bilirubin and alkaline phosphatase. This reflects the pathology associated with liver GVHD: damage to the bile canaliculi, leading to cholestasis. Temporary dilatation of the common bile duct has been described in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a rise in the serum concentration of bilirubin or alkaline phosphatase is nonspecific. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=see_link\">",
"     \"Liver biochemical tests that detect injury to hepatocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this setting, the most common confounding disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic sinusoidal obstructive syndrome (also known as hepatic veno-occlusive disease) is a relatively common toxicity associated with the use of high dose therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"       \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatic infections (primarily viral hepatitis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"       \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Effects from the preparatory regimen.",
"     </li>",
"     <li>",
"      Drug toxicity, including the drugs used for GVHD prophylaxis (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"       \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the concurrent presence of the characteristic rash provides suggestive clinical evidence, biopsy is the most definitive method to diagnose GVHD of the liver. However, this may not be feasible because of the possibility of acute bleeding due to severe thrombocytopenia soon after HCT. A transjugular hepatic biopsy may be preferred if an adequate amount of tissue can be obtained. The primary histologic finding is extensive bile duct damage (eg, bile duct atypia and degeneration, epithelial cell dropout, lymphocytic infiltration of small bile ducts), leading to occasionally severe cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the gastrointestinal tract with acute GVHD is often severe, and is characterized by diarrhea and abdominal cramping. The severity of gastrointestinal involvement is determined by the volume of diarrhea, which can occasionally exceed 10 liters per day (",
"    <a class=\"graphic graphic_table graphicRef68233 \" href=\"UTD.htm?8/63/9212\">",
"     table 1",
"    </a>",
"    ). Maintenance of adequate fluid balance may be extremely difficult in such patients. The diarrhea may initially be watery, but frequently becomes bloody, resulting in significant transfusion requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It is not unusual for patients to require two units of packed red blood cells per day to maintain a stable hematocrit.",
"   </p>",
"   <p>",
"    The crampy abdominal pain can also be difficult to treat. Severe ileus may develop in association with acute GVHD or result from increased opioid use required to control the physical discomfort.",
"   </p>",
"   <p>",
"    From a diagnostic viewpoint, diarrhea, independent of the presence of acute GVHD, is a common occurrence following HCT. During the first several weeks, diarrhea may be due to the preparatory regimen or to the administration of nonabsorbable or systemic antibiotics. Later, superinfection and Clostridium difficile-associated diarrhea must be entertained as possible causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rectal biopsy is usually helpful in making the diagnosis of acute GVHD affecting the gastrointestinal tract. On histologic examination, crypt cell necrosis is observed with the accumulation of degenerative material in the dead crypts (",
"    <a class=\"graphic graphic_picture graphicRef61225 \" href=\"UTD.htm?40/55/41845\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/11\">",
"     11",
"    </a>",
"    ]. With severe disease, whole areas may be denuded with total loss of the epithelium, a finding similar to that observed in the skin. Colonoscopy or upper endoscopy is usually also performed.",
"   </p>",
"   <p>",
"    Infection of the gastrointestinal tract, principally with cytomegalovirus, may mimic the clinical and histologic features of acute GVHD. As a result, selective staining for such pathogens should be performed on the biopsy specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Upper gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators at the University of Minnesota have described acute GVHD of the upper gastrointestinal tract characterized by anorexia, dyspepsia, food intolerance, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/17\">",
"     17",
"    </a>",
"    ]. This syndrome was verified by positive upper endoscopic biopsies of the esophagus and stomach.",
"   </p>",
"   <p>",
"    Acute GVHD affecting the upper gastrointestinal tract appears to be more responsive to immunosuppressive therapy than involvement of other areas of the gut. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .) Patients with upper gastrointestinal disease who fail treatment progress to symptomatic lower gastrointestinal involvement, findings which suggest that this syndrome may be an earlier form of intestinal pathology. Affected patients appear to be significantly older than both the overall population of HCT recipients and the cohort with grade II to IV GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hematopoietic system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less common, acute GVHD can affect the hematopoietic system. Early studies reported that the principal focus of the graft-versus-host reaction occurred in the lymphoid organs of the host. Immune competence was therefore affected, leading to frequent and possibly fatal infectious complications.",
"   </p>",
"   <p>",
"    In murine models, acute GVHD can affect hematopoiesis, leading to a reduction of precursor hematopoietic cells but not a clear decrease in peripheral blood counts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In humans, the effect of GVHD on the hematopoietic system is usually not dramatic. Persistent thrombocytopenia is a frequent manifestation and a profound drop in the serum concentration of immunoglobulins (such as IgA) may be observed.",
"   </p>",
"   <p>",
"    The development of thrombotic microangiopathy following HCT has been shown to adversely affect the survival of patients with acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute GVHD may also result in decreased responsiveness to active immunization. One study, for example, found a less effective immune response to polio vaccination in patients with GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;With acute GVHD, the induction of autoimmune disease occurring in association with autoantibody production may require the expression of particular class II haplotypes. In a murine model of GVHD, for example, the onset of lupus-like nephritis in animals producing pathogenic IgG antinuclear antibodies was dependent upon the MHC haplotype expressed by the recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are isolated case reports of patients with acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic GVHD who develop nephrotic syndrome due to membranous nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Murine models of GVHD support a direct pathogenetic association [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/24\">",
"     24",
"    </a>",
"    ]. Most patients have had stabilization in renal function and significant reductions in protein excretion after therapy with steroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperacute GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute GVHD has been traditionally (and arbitrarily) defined as a syndrome occurring during the first 100 days following HCT, with neutrophil engraftment assumed as a condition for the diagnosis. Early onset or hyperacute GVHD, which was originally seen in allogeneic HCT recipients who did not receive GVHD prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/25\">",
"     25",
"    </a>",
"    ], has been described as a clinical syndrome that can occur at any time following allogeneic infusion, independent of neutrophil engraftment, and has been associated with the use of alternative HCT donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The most severe form of hyperacute GVHD was described after haploidentical HCT, and consisted of fever, rash, and massive noncardiogenic pulmonary edema, often with renal failure and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report from the M. D. Anderson Cancer Center, hyperacute GVHD, defined as that occurring within 14 days after HCT, was seen in 27 percent of 265 patients with grade II-IV acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/29\">",
"     29",
"    </a>",
"    ]. Risk factors for hyperacute GVHD included use of a mismatched related or matched unrelated donor, a myeloablative conditioning regimen, more than five prior chemotherapy regimens, and donor-recipient sex mismatch.",
"   </p>",
"   <p>",
"    Hyperacute GVHD was associated with a significantly lower response rate to first-line GVHD therapy and a higher rate of nonrelapse mortality in patients with a mismatched related or matched unrelated donor graft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute GVHD can be readily made on clinical grounds alone in the patient who presents with a classic rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration within the first 100 days following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, however, the diagnosis is less straightforward and competing causes for isolated abnormalities must be considered and excluded. A rash alone may be caused by antibiotics or a myriad of other drugs with which these patients are often treated, diarrhea may be infectious in nature, and hyperbilirubinemia may be related to biliary sludge or a side effect of multiple drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Histologic confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic confirmation may be helpful to corroborate a clinical impression of possible acute GVHD. The skin and gastrointestinal tract are relatively easy to biopsy. As previously mentioned, percutaneous liver biopsy poses a significant risk of major bleeding since most patients are thrombocytopenic at the time of GVHD. Percutaneous transjugular liver biopsy is a safer alternative if it can be adequately performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of the pattern of plasma and urine polypeptides using proteomics has shown promise in enabling early diagnosis of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. As an example, it has been proposed that a panel of markers including Interleukin-2 receptor-alpha, tumor necrosis factor receptor-1, Interleukin-8, and hepatocyte growth factor can confirm the diagnosis of acute GVHD at the onset of clinical symptoms and provide prognostic information independent of GVHD severity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/36\">",
"     36",
"    </a>",
"    ]. Additional experience with this technique is awaited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'Proteomics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An early study in experimental animals and human subjects with biopsy-proven intestinal GVHD has suggested that imaging of the colon via 18F-FDG PET scanning may be a sensitive and specific technique for distinguishing intestinal GVHD from other competing diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25782802\">",
"    <span class=\"h1\">",
"     GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of acute GVHD is determined by an assessment of the degree of involvement of the skin, liver, and gastrointestinal tract (",
"    <a class=\"graphic graphic_table graphicRef68233 \" href=\"UTD.htm?8/63/9212\">",
"     table 1",
"    </a>",
"    ). This is subsequently combined with the results on performance scales to produce an overall grade (",
"    <a class=\"graphic graphic_table graphicRef82692 \" href=\"UTD.htm?42/15/43260\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 4",
"    </a>",
"    ). Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe and grade IV life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Grading is important in terms of assessing the response to prophylaxis or treatment, impact upon survival, and association with graft-versus-leukemia effect. Patients with moderate to severe GVHD have a significantly higher mortality rate compared with those with mild disease.",
"   </p>",
"   <p>",
"    However, the initial reports describing the correlation between overall grade and outcomes are currently less useful since they were performed prior to the widespread use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/40\">",
"     40",
"    </a>",
"    ]. Previously, prophylactic therapy for acute GVHD involved single agent therapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . By comparison, current preventive regimens involve combination therapy, which may alter overall outcomes and expressions of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients are currently seen who have grade IV GVHD of a single organ; although most clinicians would consider such a manifestation severe disease, the particular organ involved has clear prognostic implications. As an example, a patient with grade IV GVHD of the skin alone would be expected to have a much more favorable outcome than a patient with grade IV gut GVHD alone, although both have overall grade IV GVHD. As a result, several attempts have been made to create a new staging system that provides better prognostic information and permits patient comparison [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. No new staging system has yet found universal acceptance.",
"   </p>",
"   <p>",
"    The need for developing a different staging system derives from the observation that patients with the same grade but different patterns of skin, gut, or liver involvement often have significantly different outcomes. The International Bone Marrow Transplant Registry (IBMTR) grading system has come into more common usage (",
"    <a class=\"graphic graphic_table graphicRef82692 \" href=\"UTD.htm?42/15/43260\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25960/abstract/42\">",
"     42",
"    </a>",
"    ]. This system uses a severity index that was developed by grouping patients into patterns of organ involvement associated with similar risks of treatment-related mortality and treatment failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25782281\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient.",
"     </li>",
"     <li>",
"      Acute GVHD typically involves the skin, gastrointestinal tract, and liver, but may also impact the hematopoietic system, lungs, and kidneys. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical and histological manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute GVHD can be made readily on clinical grounds in the patient who presents with a classic maculopapular rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration within the first 100 days following hematopoietic cell transplantation (HCT), most often within two to three weeks following HCT. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In many cases, however, the diagnosis is less straightforward and competing causes for isolated abnormalities must be considered and excluded. Histologic confirmation may be helpful to corroborate a clinical impression of possible acute GVHD. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Histologic confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of acute GVHD is determined by an assessment of the degree of involvement of the skin, liver, and gastrointestinal tract (",
"      <a class=\"graphic graphic_table graphicRef68233 \" href=\"UTD.htm?8/63/9212\">",
"       table 1",
"      </a>",
"      ). This is subsequently combined with the results on performance scales to produce an overall grade (",
"      <a class=\"graphic graphic_table graphicRef82692 \" href=\"UTD.htm?42/15/43260\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      ). Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe and grade IV life-threatening. (See",
"      <a class=\"local\" href=\"#H25782802\">",
"       'Grading'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/1\">",
"      Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/2\">",
"      Hahn T, McCarthy PL Jr, Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26:5728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/3\">",
"      Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/4\">",
"      Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/5\">",
"      Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 101:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/6\">",
"      Sale GE, Lerner KG, Barker EA, et al. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977; 89:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/7\">",
"      Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol 1997; 21:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/8\">",
"      Darmstadt GL, Donnenberg AD, Vogelsang GB, et al. Clinical, laboratory, and histopathologic indicators of the development of progressive acute graft-versus-host disease. J Invest Dermatol 1992; 99:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/9\">",
"      Kitamura K, Asada H, Iida H, et al. Relationship among human herpesvirus 6 reactivation, serum interleukin 10 levels, and rash/graft-versus-host disease after allogeneic stem cell transplantation. J Am Acad Dermatol 2008; 58:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/10\">",
"      Ketelsen D, Vogel W, Bethge W, et al. Enlargement of the common bile duct in patients with acute graft-versus-host disease: what does it mean? AJR Am J Roentgenol 2009; 193:W181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/11\">",
"      Woodruff JM, Hansen JA, Good RA, et al. The pathology of the graft-versus-host reaction (GVHR) in adults receiving bone marrow transplants. Transplant Proc 1976; 8:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/12\">",
"      Shulman HM, Sharma P, Amos D, et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988; 8:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/13\">",
"      Snover DC, Weisdorf SA, Ramsay NK, et al. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 1984; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/14\">",
"      Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100:3903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/15\">",
"      Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/16\">",
"      Schwartz JM, Wolford JL, Thornquist MD, et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 2001; 96:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/17\">",
"      Weisdorf DJ, Snover DC, Haake R, et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/18\">",
"      Iwasaki T, Fujiwara H, Iwasaki T, Shearer GM. Loss of proliferative capacity and T cell immune development potential by bone marrow from mice undergoing a graft-vs-host reaction. J Immunol 1986; 137:3100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/19\">",
"      Shono Y, Ueha S, Wang Y, et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood 2010; 115:5401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/20\">",
"      Cho BS, Min CK, Eom KS, et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/21\">",
"      Engelhard D, Handsher R, Naparstek E, et al. Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/22\">",
"      Portanova JP, Ebling FM, Hammond WS, et al. Allogeneic MHC antigen requirements for lupus-like autoantibody production and nephritis in murine graft-vs-host disease. J Immunol 1988; 141:3370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/23\">",
"      Lin J, Markowitz GS, Nicolaides M, et al. Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literature. Am J Nephrol 2001; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/24\">",
"      Barbara JA, Thomas AC, Smith PS, et al. Membranous nephropathy with graft-versus-host disease in a bone marrow transplant recipient. Clin Nephrol 1992; 37:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/25\">",
"      Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/26\">",
"      Kim DH, Sohn SK, Kim JG, et al. Clinical impact of hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/27\">",
"      Deeg HJ, Antin JH. The clinical spectrum of acute graft-versus-host disease. Semin Hematol 2006; 43:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/28\">",
"      Powles R, Pedrazzini A, Crofts M, et al. Mismatched family bone marrow transplantation. Semin Hematol 1984; 21:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/29\">",
"      Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/30\">",
"      Firoz BF, Lee SJ, Nghiem P, Qureshi AA. Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol 2006; 142:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/31\">",
"      Lunn RA, Sumar N, Bansal AS, Treleaven J. Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology 2005; 10:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/32\">",
"      Srinivasan R, Daniels J, Fusaro V, et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006; 34:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/33\">",
"      Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:5511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/34\">",
"      Hori T, Naishiro Y, Sohma H, et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 2008; 111:4403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/35\">",
"      Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012; 119:2960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/36\">",
"      Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/37\">",
"      Stelljes M, Hermann S, Albring J, et al. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood 2008; 111:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/38\">",
"      Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/39\">",
"      Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle et Th&eacute;rapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 106:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/40\">",
"      Vogelsang GB, Hess AD, Santos GW. Acute graft-versus-host disease: clinical characteristics in the cyclosporine era. Medicine (Baltimore) 1988; 67:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/41\">",
"      Vogelsang GB, Wagner JE. Graft-versus-host disease. Hematol Oncol Clin North Am 1990; 4:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/42\">",
"      Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25960/abstract/43\">",
"      Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108:749.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3549 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25960=[""].join("\n");
var outline_f25_22_25960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25782281\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25782620\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL AND HISTOLOGICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Upper gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hematopoietic system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperacute GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Histologic confirmation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25782802\">",
"      GRADING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25782281\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3549\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3549|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/28/41409\" title=\"picture 1\">",
"      Skin disease in acute GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/4/23620\" title=\"picture 2\">",
"      Skin in acute GVHD light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/55/41845\" title=\"picture 3\">",
"      Rectal biopsy in acute GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3549|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/63/9212\" title=\"table 1\">",
"      Grade GVHD by organ system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/15/43260\" title=\"table 2\">",
"      Overall grading of acute GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 3\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42073?source=related_link\">",
"      Cutaneous manifestations of graft-versus-host disease (GVHD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=related_link\">",
"      Liver biochemical tests that detect injury to hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_22_25961="Evaluation and management of supracondylar fractures in children";
var content_f25_22_25961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of supracondylar fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25961/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25961/contributors\">",
"     Leticia Manning Ryan, MD, MPH, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25961/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25961/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/22/25961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supracondylar fractures are the most common pediatric elbow fracture and carry significant potential for neurovascular compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These fractures of the distal humerus are frequently problematic in terms of diagnosis, treatment, and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/1\">",
"     1",
"    </a>",
"    ]. Proper care requires appropriate assessment and prompt orthopedic care for those patients whose fractures pose the greatest risk for long-term complications.",
"   </p>",
"   <p>",
"    This topic will discuss the evaluation and treatment of supracondylar fractures in children. Other distal humeral fractures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19175?source=see_link\">",
"     \"Evaluation and management of condylar elbow fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=see_link\">",
"     \"Epicondylar and transphyseal elbow fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supracondylar fractures account for up to 60 percent of pediatric elbow fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/4\">",
"     4",
"    </a>",
"    ]. They occur most frequently in children between 5 and 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/5\">",
"     5",
"    </a>",
"    ]. Supracondylar fractures result from a fall on an outstretched arm in up to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/6\">",
"     6",
"    </a>",
"    ]. The nondominant extremity is most commonly affected. Children under three years of age typically sustain a supracondylar fracture after a fall from a height of less than three feet (eg, fall from a bed or couch). Most fractures in older children result from higher falls from playground equipment (eg, monkey bars, swings) or other high energy mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the supracondylar region encompasses an area of thin, weak bone located in the distal humerus. This region is bordered posteriorly by the olecranon fossa and anteriorly by the coronoid fossa (",
"    <a class=\"graphic graphic_figure graphicRef66099 \" href=\"UTD.htm?29/25/30111\">",
"     figure 1",
"    </a>",
"    ). The medial and lateral aspects of the supracondylar region extend distally to the developing medial and lateral condyles and epicondyles.",
"   </p>",
"   <p>",
"    When a child falls onto an outstretched arm with the elbow in hyperextension, the force of the fall is transmitted through the olecranon to the weak supracondylar region, causing a supracondylar fracture. Depending on the severity of the fracture, posterior displacement of the distal fracture fragment and anterior displacement of the proximal fracture fragment may occur (",
"    <a class=\"graphic graphic_figure graphicRef54389 \" href=\"UTD.htm?3/60/4036\">",
"     figure 2",
"    </a>",
"    ). The fracture line typically propagates transversely across the distal humerus through the center of the olecranon fossa (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56874 \" href=\"UTD.htm?10/53/11088\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Supracondylar fracture classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Soft tissue structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In more severe supracondylar fractures (especially type III), the proximal fragment of the distal fractured humerus is driven anteriorly into soft tissue structures with potential impingement on important blood vessels and nerves. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Supracondylar fracture classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Vascular anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brachial artery is superficial to the brachialis muscle along the anteromedial aspect of the humerus. As the brachial artery passes anterior to the distal humerus, an extensive collateral circulation develops. As the artery extends into the forearm, it splits into the radial and ulnar artery (",
"    <a class=\"graphic graphic_figure graphicRef82540 \" href=\"UTD.htm?22/52/23365\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with posterolateral displacement of a supracondylar fracture, the brachial artery may be injured when the proximal fragment of the fractured humerus moves medially, piercing the brachialis muscle and reaching the brachial artery (",
"    <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"     figure 4",
"    </a>",
"    ). In addition, the brachial artery may be tethered to the sharp edge of the proximal fracture fragment by the supratrochlear branch of the anterior ulnar recurrent artery, thereby increasing the risk of brachial artery injury during movement of the injured arm or fracture manipulation (",
"    <a class=\"graphic graphic_figure graphicRef57069 \" href=\"UTD.htm?19/56/20354\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    \"Scraping\" of the brachial artery by the bony fragment may result in intimal damage to the vessel. This injury may subsequently lead to thrombosis and vascular insufficiency. Because of the extensive collateral circulation present at the elbow, it is rare for ischemia of the arm to occur from complete brachial artery occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8\">",
"     8",
"    </a>",
"    ]. Median nerve injury often accompanies brachial artery impingement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nerve anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a displaced supracondylar fracture, the median (including the anterior interosseous nerve branch), radial, and ulnar nerves are at potential risk for injury (",
"    <a class=\"graphic graphic_figure graphicRef82540 \" href=\"UTD.htm?22/52/23365\">",
"     figure 3",
"    </a>",
"    ). Although nerve injuries may rarely be associated with long term sequelae, the majority are neurapraxias, such as temporary loss of nerve function (especially motor function) without anatomical nerve disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median nerve crosses the elbow joint with the brachial artery. Posterolateral distal fracture fragment displacement with medial movement of the proximal fracture fragment puts the median nerve and its anterior interosseous nerve branch at the greatest risk of injury (",
"      <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"       figure 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Median nerve injury results in weakness of the flexor muscles of the hand and loss of two-point sensation on the palmar surface of the thumb and the index and middle fingers [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/10\">",
"       10",
"      </a>",
"      ]. The anterior interosseous nerve (AION) is the branch of the median nerve most commonly injured (",
"      <a class=\"graphic graphic_figure graphicRef82540 \" href=\"UTD.htm?22/52/23365\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. The AION lacks a superficial sensory component [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Children and adolescents with AION syndrome initially have proximal forearm pain followed by weakness in the hand with no sensory deficits. On physical examination they have a weak \"OK sign\"",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a lack of distal interphalangeal flexion when making an OK sign (eg, more of a pincer grasp than an OK sign) (",
"      <a class=\"graphic graphic_picture graphicRef52203 \" href=\"UTD.htm?25/33/26142\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Neurologic deficit'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The radial nerve runs between the brachialis and brachioradialis muscles before crossing the elbow and penetrating the supinator muscle. Posteromedial distal fracture fragment displacement increases the chance of radial nerve impingement because of lateral proximal fracture fragment displacement (",
"      <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/12\">",
"       12",
"      </a>",
"      ]. Injury to the radial nerve results in weakness of wrist extension, hand supination, and thumb extension. In addition, altered sensation is found in the dorsal web space between the thumb and index finger.",
"     </li>",
"     <li>",
"      The ulnar nerve crosses the elbow posterior to the medial epicondyle and is typically not affected with extension type supracondylar fractures. However, it is prone to injury following flexion type supracondylar fractures (",
"      <a class=\"graphic graphic_figure graphicRef77891 \" href=\"UTD.htm?33/15/34034\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8\">",
"       8",
"      </a>",
"      ]. Ulnar nerve injury causes weakness of wrist flexion and adduction, finger spread, and flexion of the distal phalanx of the fifth digit (pinky or little finger). These motor findings are accompanied by altered sensation of the ulnar side of the ring (fourth digit) and little fingers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, fractures of the distal humerus are most commonly due to a fall on an outstretched hand (FOOSH) or direct trauma to the elbow [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Extension and flexion are the two major types of supracondylar fracture and each has a characteristic mechanism of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extension fractures account for approximately 95 percent of supracondylar fractures and typically result from a FOOSH mechanism with the elbow hyperextended [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. The distal condylar complex may then shift in either the posterolateral or posteromedial direction (",
"    <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Supracondylar flexion fractures account for 5 percent of supracondylar fractures. In contrast to extension injuries, these fractures result from a direct blow to the posterior aspect of the flexed elbow. In these cases, the distal condylar complex is more likely to displace in the anterolateral direction (",
"    <a class=\"graphic graphic_figure graphicRef77891 \" href=\"UTD.htm?33/15/34034\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3,8,13\">",
"     3,8,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with a supracondylar fracture typically has elbow pain, swelling, and very limited to no range of motion at the elbow [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8\">",
"     8",
"    </a>",
"    ]. The clinician must rapidly assess the injury to identify degree of fracture displacement, neurovascular compromise, and evidence of compartment syndrome.",
"   </p>",
"   <p>",
"    One approach is to initially inspect the affected arm and perform a brief neurovascular examination followed by a more complete evaluation once pain is controlled and radiographs have been obtained. The clinician should not encourage active or passive elbow movement in a patient with a suspected supracondylar fracture until a displaced fracture has been excluded by radiography. Patients with an obviously displaced supracondylar fracture require initial immobilization before radiography is performed. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Neurovascular examination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Analgesia and immobilization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should carefully inspect the anterior and posterior arm for wounds that indicate an open fracture while limiting movement of the injured arm. In patients transferred by ambulance or from another hospital, this task often requires careful removal of previously applied immobilization devices. Open supracondylar fractures often manifest as a puncture wound or laceration in or just above the antecubital region.",
"   </p>",
"   <p>",
"    Displaced fractures may have an \"S-shaped\" configuration or dimpling in the antecubital fossa associated with marked swelling about the elbow (",
"    <a class=\"graphic graphic_figure graphicRef60885 \" href=\"UTD.htm?15/60/16321\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56554 \" href=\"UTD.htm?34/49/35600\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ecchymosis over the anteromedial aspect of the forearm suggests brachial artery injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nondisplaced fractures may have minimal swelling, but observation will show that the child is not using the affected arm normally. Posterior distal humeral palpation is usually painful in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurovascular examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete neurovascular evaluation includes an assessment of radial and brachial pulses and the sensory and motor function of the median, radial, and ulnar nerves (",
"    <a class=\"graphic graphic_table graphicRef53902 \" href=\"UTD.htm?24/11/24763\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with a normal initial neurovascular examination warrant regular repeated evaluation, especially immediately following splinting, fracture manipulation, or movement of the affected extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pulse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should compare the radial and brachial pulse with the opposite limb. Initially symmetric and equal pulses with normal perfusion and skin warmth are reassuring but do not entirely exclude vascular injury. However, patients who maintain normal pulse and perfusion over time are unlikely to have a brachial artery injury.",
"   </p>",
"   <p>",
"    If a radial or brachial pulse is not palpable, a Doppler ultrasound should be used to determine the presence of distal perfusion. Pulse oximetry may also provide evidence of pulsatile flow as well as degree of oxygenation distal to the injury. If the pulse oximetry provides a wave form and oxygen saturation, then it can be used to provide continuous information on distal extremity perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brisk capillary refill, normal color, and a warm hand indicate the presence of some distal perfusion, even when distal pulses are diminished or absent. Maintenance of perfusion despite abnormal pulses often arises from brachial artery spasm that typically resolves after urgent closed reduction and percutaneous pinning.",
"   </p>",
"   <p>",
"    However, diminished or absent pulses in association with poor distal perfusion, pallor, and a cool hand are concerning signs of ischemia, especially in association with pain upon passive extension of the fingers. Patients with these findings warrant emergent intervention to reestablish limb perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Compartment syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Absent pulse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Neurologic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should evaluate the sensory and motor function of the median, radial, and ulnar nerves while minimizing patient discomfort (",
"    <a class=\"graphic graphic_table graphicRef53902 \" href=\"UTD.htm?24/11/24763\">",
"     table 1",
"    </a>",
"    ). In a patient with an extremely painful injury, analgesia (eg, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose: 10 mg) prior to examination is necessary to enable the child to cooperate with the examination.",
"   </p>",
"   <p>",
"    The following tests establish motor function of the major nerves while minimizing extremity movements. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Nerve anatomy'",
"    </a>",
"    above.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"OK\" sign (alternatively, ask the patient to pinch your hand): anterior interosseous nerve (branch of median nerve and radial nerve) (",
"      <a class=\"graphic graphic_picture graphicRef52203 \" href=\"UTD.htm?25/33/26142\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Finger spread against resistance or holding a piece of paper firmly between the middle and ring fingers: ulnar nerve (",
"      <a class=\"graphic graphic_figure graphicRef75179 \" href=\"UTD.htm?23/56/24463\">",
"       figure 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thumb's up sign: radial nerve (",
"      <a class=\"graphic graphic_figure graphicRef51625 \" href=\"UTD.htm?14/7/14463\">",
"       figure 10",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should perform testing of two point discrimination (ie, the ability to recognize two points five millimeters apart applied simultaneously to the skin as distinct from a single point) on the follow sites to evaluate peripheral nerve sensation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dorsal web space - Innervated by the radial nerve",
"     </li>",
"     <li>",
"      Palmar index (pointer) finger - Innervated by the median nerve",
"     </li>",
"     <li>",
"      Pinky (or little finger) - Innervated by the ulnar nerve",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although nerve injuries may rarely be associated with long term sequelae, the majority are neurapraxias, ie, temporary loss of nerve function (especially motor function) without anatomical nerve disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings suggest a developing compartment syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive swelling and ecchymosis at the elbow [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increasing forearm pain",
"     </li>",
"     <li>",
"      Increased pain upon passive extension of the fingers",
"     </li>",
"     <li>",
"      Cold hand with poor perfusion, pallor, and diminished or absent pulse (late finding)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compartment syndrome may occur prior to or after definitive orthopedic care but is rare (&lt;1 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/7\">",
"     7",
"    </a>",
"    ]. It is more common in children with supracondylar fracture who also have a forearm fracture. Once the clinician suspects an acute compartment syndrome, compartment pressures must be measured to determine whether they are elevated, or a clinical decision to perform a fasciotomy is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forearm and wrist fractures occasionally complicate supracondylar fractures in children. Thus, the forearm and wrist warrant careful inspection for swelling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity and palpation for bony tenderness. Radiographs of these areas should be routinely ordered in children with supracondylar fractures. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Radiographic views'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, shoulder and clavicle injuries may occur and any deformity, swelling, or bony tenderness in these areas warrants radiographic investigation.",
"   </p>",
"   <p>",
"    Most supracondylar fractures result from falls on an outstretched arm and are not associated with multiple trauma. However, children who fall from a height greater than three times their standing height or 10 feet, whichever is less, are at increased risk for multiple trauma to the head, thorax, and abdomen and may warrant, in addition to a complete physical examination, appropriate ancillary studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\", section on 'Approach to blunt trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H8#H8\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with a suspected supracondylar fracture should receive a general assessment as well as a focused physical examination of the involved extremity. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Physical findings'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radiologic technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate analgesia should be provided BEFORE extremity radiographs are obtained. When obtaining radiographs in the child with a supracondylar fracture, the goal is to obtain the necessary films with minimal movement of the extremity. Excessive manipulation of the extremity during radiologic procedures may further exacerbate or precipitate neurovascular injury, especially in patients with an unstable type II or type III supracondylar fracture.",
"   </p>",
"   <p>",
"    In patients with evidence of severe fracture (S-shape configuration or pucker sign, (",
"    <a class=\"graphic graphic_figure graphicRef60885 \" href=\"UTD.htm?15/60/16321\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56554 \" href=\"UTD.htm?34/49/35600\">",
"     figure 8",
"    </a>",
"    )), splinting is advisable prior to obtaining radiographs. Alternatively, the clinician and an assistant may accompany the patient and assist with positioning of the obviously deformed extremity while ensuring neurovascular status does not deteriorate. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Analgesia and immobilization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients without obvious deformity, a sling typically provides adequate support for nondisplaced fractures and allows for radiographs to be obtained more easily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radiographic views",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic assessment of suspected supracondylar fracture requires a true lateral of the elbow with the humerus in anatomic position (",
"    <a class=\"graphic graphic_figure graphicRef71799 \" href=\"UTD.htm?20/33/21009\">",
"     figure 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56647 \" href=\"UTD.htm?23/2/23586\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because of the association of supracondylar fractures with forearm fractures, the clinician should also obtain AP and lateral radiographic views of the forearm. In many hospitals, this requirement is accomplished by including the entire forearm in the AP and lateral views of the elbow. This approach saves time and minimizes movement of the extremity.",
"   </p>",
"   <p>",
"    Proximal humerus, clavicle, and wrist radiographs may also be necessary depending on the patient's physical findings. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Associated fractures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Supracondylar fracture classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extension type supracondylar fractures may be further classified according to the Gartland classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I &ndash; Gartland type I supracondylar fracture describes a nondisplaced fracture with radiographic evidence of elbow effusion (anterior sail",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior fat pad signs). Because the anterior and posterior periosteum remains intact, the anterior humeral line transects the middle third of the capitellum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55523 \" href=\"UTD.htm?23/16/23823\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19607?source=see_link&amp;anchor=H13#H13\">",
"       \"Elbow anatomy and radiographic diagnosis of elbow fracture in children\", section on 'Fat pads'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type II &ndash; Gartland type II supracondylar fracture refers to a displaced fracture with an intact posterior periosteum. In contrast to type I fractures, the anterior humeral line is displaced anteriorly, either hitting the anterior third of the capitellum or missing it entirely, indicating posterior displacement of the distal humeral fracture. In most children, the fracture line is clearly seen and \"hinging\" of the posterior periosteum and posterior displacement of the distal fracture fragment may occur (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64760 \" href=\"UTD.htm?31/53/32607\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77570 \" href=\"UTD.htm?11/61/12240\">",
"       image 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19607?source=see_link&amp;anchor=H11#H11\">",
"       \"Elbow anatomy and radiographic diagnosis of elbow fracture in children\", section on 'Anterior humeral line'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type III &ndash; Gartland type III supracondylar fracture is a displaced fracture with disrupted anterior and posterior periosteum. This injury results in no continuity between the proximal and distal fracture fragments. Type III fractures may be displaced in three directions: posteromedial (the most common pattern), posterolateral, or anterolateral. The direction of displacement is important in determining which neurovascular structures are at greatest risk for injury (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73852 \" href=\"UTD.htm?18/0/18432\">",
"       image 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Soft tissue structures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Associated fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supracondylar fractures are associated with forearm or distal radius fractures in up to 5 percent of cases. The combination of supracondylar and forearm fractures increases the possibility of compartment syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. For this reason, radiographs of the forearm should be obtained in all patients with supracondylar fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proximal humerus, clavicle, and wrist fractures may also occur with a supracondylar fracture. Deformity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bony tenderness during physical examination dictate appropriate radiographic assessment of these areas in selected patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57479 \" href=\"UTD.htm?23/55/24432\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51211 \" href=\"UTD.htm?27/31/28155\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Absent pulse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency clinician should promptly identify children with vascular insufficiency and emergently involve an orthopedic surgeon with appropriate pediatric expertise. Rarely, these children will require partial closed reduction in the emergency department in an attempt to restore distal circulation (",
"    <a class=\"graphic graphic_figure graphicRef68664 \" href=\"UTD.htm?22/15/22769\">",
"     figure 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients who display a cold, white or cyanotic hand despite reduction attempts require operative exploration and vascular repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Acute compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compartment syndrome may occur prior to or after definitive orthopedic care. It is more common in children with supracondylar fracture who also have a forearm fracture. Suspected compartment syndrome should prompt measurement of compartment pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emergent consultation with an orthopedic surgeon with pediatric expertise. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Compartment syndrome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Measurement of compartment pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once confirmed by compartment pressure measurement or by clinical examination by an orthopedic surgeon, immediate management of suspected acute compartment syndrome includes relieving all external pressure on the compartment. Any dressing, splint, cast, or other restrictive covering should be removed. The limb should NOT be elevated. Elevation can diminish arterial inflow and exacerbate ischemia. Analgesics should be given. Definitive treatment consists of fasciotomy to decompress all involved compartments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Analgesia and immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with adequate distal circulation and no sign of compartment syndrome, initial therapy consists of pain management and immobilization to prevent further distraction of the fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral analgesia (eg, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      0.1 to 0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum single dose: 10 mg) is most appropriate for initial pain control in patients with moderate to severe pain and should be given prior to radiographic evaluation. Oral analgesia (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      may suffice for patients who have suffered a nondisplaced supracondylar fracture. In most circumstances, pain relief will result in an improved ability to assess neurovascular status in the apprehensive child.",
"     </li>",
"     <li>",
"      Immobilization is particularly important prior to radiographs in children with significantly deformed fractures. Splinting avoids additional soft tissue injury from inadvertent arm movement. In this situation, the arm should be splinted \"as it lies\" (typically with elbow flexed 20 to 30 degrees) using prefabricated splinting material or eight layers of plaster with under cast padding (eg, Webril&reg;). A loosely applied elastic bandage (eg, Ace&reg; wrap) holds the splint in place. Neurovascular status should be checked before and after splinting. If any further compromise is found after immobilization, then the splinting material should be removed and the arm position adjusted. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Absent pulse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Radiologic technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Orthopedic consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt orthopedic consultation should be obtained in any of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open supracondylar fracture",
"     </li>",
"     <li>",
"      Fracture with neurovascular compromise",
"     </li>",
"     <li>",
"      Type II or type III supracondylar fracture",
"     </li>",
"     <li>",
"      Supracondylar fracture with evidence of compartment syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DEFINITIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment varies for each type of supracondylar fracture:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Type I fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a nondisplaced Type I fracture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55523 \" href=\"UTD.htm?23/16/23823\">",
"     image 4",
"    </a>",
"    ) may be immobilized using either a collar and cuff sling or a posterior splint and sling. If a posterior splint is placed, it should extend from the wrist to the axilla, with the elbow at 90 degrees of flexion and the forearm in neutral position with respect to supination and pronation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized trial of 50 children found that those immobilized initially in a posterior splint and sling returned to normal activity sooner than those immobilized in a collar and cuff sling (median 2 versus 7 days, p&le;0.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/17\">",
"     17",
"    </a>",
"    ]. The study found no difference between the two groups in daily pain scores or in resumption of normal activity or mobility at two weeks.",
"   </p>",
"   <p>",
"    Circumferential casting and extremes of flexion should be initially avoided in most cases to decrease the incidence of compartment syndrome and vascular compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9,18\">",
"     9,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical duration of immobilization for nondisplaced type I supracondylar fractures is three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Type II fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64760 \" href=\"UTD.htm?31/53/32607\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77570 \" href=\"UTD.htm?11/61/12240\">",
"     image 6",
"    </a>",
"    ) require orthopedic consultation for the determination of appropriate intervention (closed versus open reduction with percutaneous pin placement). Most pediatric orthopedists now recommend closed reduction and percutaneous pin fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Type III fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type III supracondylar fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73852 \" href=\"UTD.htm?18/0/18432\">",
"     image 7",
"    </a>",
"    ) require orthopedic consultation for the determination of appropriate intervention (closed versus open reduction with percutaneous pin placement) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with nondisplaced fractures (eg, Gartland type I fractures) do not require immediate orthopedic evaluation. After splinting, these patients may be referred for follow up within seven days of the injury. The family should be instructed to return immediately for signs of unmanageable pain or compartment syndrome. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Compartment syndrome'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Supracondylar fracture classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Almost all children with displaced supracondylar fractures (eg, Gartland type II and III fractures) require open or closed reduction and percutaneous pinning. Hospital admission for monitoring of pulses, nerve function, and forearm compartments is also typical. After discharge, the patient is maintained in a splint or cast with percutaneous pins. Repeat radiographs are obtained on a regular basis to assess bone healing. Pins are removed when the distal humerus is no longer tender, usually in three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After pin and cast removal, motion exercises may be recommended as tolerated. Studies of children with supracondylar fractures and no neurovascular deficit suggest that formal physical therapy does not appear to improve long term mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/20\">",
"     20",
"    </a>",
"    ]. However, physical therapy is recommended for children with persistent contractures after three to four months or nerve deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of supracondylar fractures include vascular insufficiency, forearm compartment syndrome resulting in Volkmann's ischemic contracture, nerve injury, and cubitus varus deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Vascular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absence of the radial pulse is reported in up to 10 to 20 percent of all supracondylar fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/21\">",
"     21",
"    </a>",
"    ]. Vascular injury is most common with type II and III supracondylar fractures (",
"    <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/13,22\">",
"     13,22",
"    </a>",
"    ]. The brachial artery is most frequently injured in posterolaterally displaced fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients without significant improvement in pulse or Doppler pulse after orthopedic care warrant emergent vascular exploration, especially if perfusion is not restored or if intractable pain suggestive of ischemia is present [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/4,22-24\">",
"     4,22-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 161 children with supracondylar fractures and a pulseless hand found that closed reduction and percutaneous pinning resulted in return of the radial pulse in 51 percent (82 of 161) of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/22\">",
"       22",
"      </a>",
"      ]. Sixty-three of 79 children with persistent pulseless hand after operative care underwent vascular exploration. Brachial artery injury or thrombus was found in 61 patients (97 percent).",
"     </li>",
"     <li>",
"      An observational study of 19 children who had a perfused but pulseless hand after operative fixation found that the eight children who also had a median",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anterior interosseus nerve deficit demonstrated entrapment of both the brachial artery and the median nerve at the fracture site [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/23\">",
"       23",
"      </a>",
"      ]. Among the 11 children who were treated with closed reduction followed by observation, four patients underwent secondary exploration between two days and three weeks after injury; the brachial artery was running through the fracture site in all patients and one developed a persistent median nerve deficit.",
"     </li>",
"     <li>",
"      An observational study of 26 children who had a pink pulseless hand after initial treatment of a supracondylar fracture found that the 23 children who presented four days to one year after injury and did not have early release of brachial artery obstruction developed ischemic contractions of hand",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      forearm muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/24\">",
"       24",
"      </a>",
"      ]. They also had 56 nerve injuries of which 41 were directly attributable to muscle ischemia and compression. Approximately half of these nerve injuries responded to late operative exploration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Volkmann ischemic contracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular injury and primary swelling from the injury can lead to the development of compartment syndrome within 12 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/15\">",
"     15",
"    </a>",
"    ]. If a compartment syndrome is not treated in a timely manner, the associated ischemia and infarction may progress to Volkmann's ischemic contracture: fixed flexion of the elbow, pronation of the forearm, flexion at the wrist, and joint extension of the metacarpal-phalangeal joint [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Neurologic deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of neurologic deficit after supracondylar fractures is 10 to 20 percent and increases in some series of children with type III supracondylar fractures to as high as 49 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/5,7,12,25\">",
"     5,7,12,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterolateral distal fracture fragment displacement with medial movement of the proximal fracture fragment puts the median nerve and its anterior interosseous nerve branch at the greatest risk of injury (",
"      <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Posteromedial distal fracture fragment displacement increases the chance of radial nerve impingement because of lateral proximal fracture fragment displacement (",
"      <a class=\"graphic graphic_figure graphicRef72056 \" href=\"UTD.htm?43/35/44593\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ulnar nerve injuries are most commonly associated with flexion type supracondylar fractures (",
"      <a class=\"graphic graphic_figure graphicRef77891 \" href=\"UTD.htm?33/15/34034\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/5,11,25\">",
"       5,11,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although nerve injuries may be associated with long-term sequelae, the majority are neurapraxias that will resolve within two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9,25,26\">",
"     9,25,26",
"    </a>",
"    ]. Surgical exploration should be considered for nerve deficits that persist beyond three months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/8,12,20\">",
"     8,12,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Cubitus varus deformity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angular deformity (cubitus varus or \"gunstock\" deformity) is a long term complication of a supracondylar fracture (",
"    <a class=\"graphic graphic_figure graphicRef63539 \" href=\"UTD.htm?17/52/18255\">",
"     figure 13",
"    </a>",
"    ). In contrast to the proximal humeral physis, the distal humerus physis contributes little (15 to 20 percent) to the overall longitudinal growth of the humerus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, remodeling and correction of fracture angulation is limited for children with supracondylar fractures.",
"   </p>",
"   <p>",
"    Modern surgical techniques (eg, closed reduction with percutaneous pinning) have reduced the frequency of cubitus varus from 58 to approximately 3 percent of children treated for supracondylar fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/6\">",
"     6",
"    </a>",
"    ]. Cubitus varus deformity is mainly cosmetic and function is usually preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/4\">",
"     4",
"    </a>",
"    ]. However, it is rarely associated with an ulnar nerve palsy that may present many years after the original fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although immediate complications of distal humeral fractures are common in the pediatric population, the prognosis for long term outcome and function is very good if the fracture is appropriately diagnosed and treated. Many of the associated complications either are self limited or are amenable to functional repair with surgical intervention.",
"   </p>",
"   <p>",
"    For instance, vascular insufficiency often resolves after orthopedic alignment with percutaneous pinning. Similarly, nerve injury typically results from neurapraxia, ie, temporary nerve dysfunction that resolves without long term effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/9,26\">",
"     9,26",
"    </a>",
"    ]. In addition, joint stiffness may also be treated surgically in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/3,29\">",
"     3,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 108 supracondylar fractures with complete follow up, 99 children had an excellent outcome, 5 had a good outcome, and 4 had a poor outcome. The poor results were attributed to technical errors in reduction resulting in an unsatisfactory cosmetic outcome but good function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/35/20018?source=see_link\">",
"       \"Patient information: Elbow fracture in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, the supracondylar region encompasses an area of thin, weak bone located in the distal posterior humerus. Fracture in this region is common after a fall on an outstretched hand and may lead to neurovascular compromise. In particular, the anterior interosseous branch of the median nerve and the brachial artery are at risk of injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pertinent anatomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child with a supracondylar fracture typically has elbow pain, swelling, and very limited to no range of motion at the elbow. The clinician must rapidly assess the injury to identify neurovascular compromise, evidence of compartment syndrome, and degree of fracture displacement. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate analgesia should be provided BEFORE extremity radiographs are obtained. Radiographic assessment of suspected supracondylar fracture requires a true lateral of the elbow, if permitted by the patient's clinical condition, with the humerus in anatomic position and an anteroposterior (AP) projection of the distal humerus (",
"      <a class=\"graphic graphic_table graphicRef51211 \" href=\"UTD.htm?27/31/28155\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71799 \" href=\"UTD.htm?20/33/21009\">",
"       figure 11",
"      </a>",
"      ). Because of the association of supracondylar fractures with forearm fractures, the clinician should also obtain AP and lateral radiographic views of the forearm. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiographic assessment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19607?source=see_link&amp;anchor=H9#H9\">",
"       \"Elbow anatomy and radiographic diagnosis of elbow fracture in children\", section on 'Plain radiograph interpretation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with evidence of deformity or severe fracture (eg, S-shape configuration or pucker sign, (",
"      <a class=\"graphic graphic_figure graphicRef60885 \" href=\"UTD.htm?15/60/16321\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56554 \" href=\"UTD.htm?34/49/35600\">",
"       figure 8",
"      </a>",
"      )), splinting is advisable prior to obtaining radiographs. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiographic assessment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19607?source=see_link&amp;anchor=H9#H9\">",
"       \"Elbow anatomy and radiographic diagnosis of elbow fracture in children\", section on 'Plain radiograph interpretation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The emergency clinician should promptly identify children with vascular insufficiency and emergently involve an orthopedic surgeon with pediatric expertise. Rarely, these children will require partial closed reduction in the emergency department in an attempt to restore distal circulation (",
"      <a class=\"graphic graphic_figure graphicRef68664 \" href=\"UTD.htm?22/15/22769\">",
"       figure 12",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25961/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients who display a cold, cyanotic hand despite reduction attempts require emergent operative exploration and vascular repair. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pulse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Perfusion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Absent pulse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suspected compartment syndrome should prompt measurement of compartment pressure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      emergent consultation with an orthopedic surgeon with appropriate pediatric expertise. Once confirmed by compartment pressure measurement, immediate management of suspected acute compartment syndrome includes relieving all external pressure on the compartment. Definitive treatment consists of fasciotomy to decompress all involved compartments. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Compartment syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H10#H10\">",
"       \"Acute compartment syndrome of the extremities\", section on 'Measurement of compartment pressures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children with adequate distal circulation and no sign of compartment syndrome, initial therapy consists of pain management and immobilization to prevent further displacement of the fracture. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Analgesia and immobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent orthopedic consultation is indicated for children with an open fracture, neurovascular compromise, or acute compartment syndrome. In addition, prompt involvement of an orthopedic surgeon is necessary for operative care of a child with a Type II or Type III supracondylar fracture. Nondisplaced Type I supracondylar fractures are treated with a long arm splint with orthopedic follow up in one week. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Supracondylar fracture classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Neurologic deficit'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Type I fracture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Type II fracture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Type III fracture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bachman D, Santora S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, et al.  (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.1538.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/2\">",
"      Della-Giustina K, Della-Giustina DA. Emergency department evaluation and treatment of pediatric orthopedic injuries. Emerg Med Clin North Am 1999; 17:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/3\">",
"      Carson S, Woolridge DP, Colletti J, Kilgore K. Pediatric upper extremity injuries. Pediatr Clin North Am 2006; 53:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/4\">",
"      Lins RE, Simovitch RW, Waters PM. Pediatric elbow trauma. Orthop Clin North Am 1999; 30:119.",
"     </a>",
"    </li>",
"    <li>",
"     Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.577.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/6\">",
"      Farnsworth CL, Silva PD, Mubarak SJ. Etiology of supracondylar humerus fractures. J Pediatr Orthop 1998; 18:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/7\">",
"      Fletcher N, Schiller JR, Sumeet G, et al. Increased severity of type III supracondylar humeral fractures in the preteen population. J Pediatr 2012; 32:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/8\">",
"      Baratz M, Micucci C, Sangimino M. Pediatric supracondylar humerus fractures. Hand Clin 2006; 22:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/9\">",
"      Villarin LA Jr, Belk KE, Freid R. Emergency department evaluation and treatment of elbow and forearm injuries. Emerg Med Clin North Am 1999; 17:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/10\">",
"      Jones ET, Louis DS. Median nerve injuries associated with supracondylar fractures of the humerus in children. Clin Orthop Relat Res 1980; :181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/11\">",
"      Brown IC, Zinar DM. Traumatic and iatrogenic neurological complications after supracondylar humerus fractures in children. J Pediatr Orthop 1995; 15:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/12\">",
"      Campbell CC, Waters PM, Emans JB, et al. Neurovascular injury and displacement in type III supracondylar humerus fractures. J Pediatr Orthop 1995; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/13\">",
"      Skaggs D, Pershad J. Pediatric elbow trauma. Pediatr Emerg Care 1997; 13:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/14\">",
"      Shrader MW. Pediatric supracondylar fractures and pediatric physeal elbow fractures. Orthop Clin North Am 2008; 39:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/15\">",
"      Wu J, Perron AD, Miller MD, et al. Orthopedic pitfalls in the ED: pediatric supracondylar humerus fractures. Am J Emerg Med 2002; 20:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/16\">",
"      Roposch A, Reis M, Molina M, et al. Supracondylar fractures of the humerus associated with ipsilateral forearm fractures in children: a report of forty-seven cases. J Pediatr Orthop 2001; 21:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/17\">",
"      Oakley E, Barnett P, Babl FE. Backslab versus nonbackslab for immobilization of undisplaced supracondylar fractures: a randomized trial. Pediatr Emerg Care 2009; 25:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/18\">",
"      McGraw JJ, Akbarnia BA, Hanel DP, et al. Neurological complications resulting from supracondylar fractures of the humerus in children. J Pediatr Orthop 1986; 6:647.",
"     </a>",
"    </li>",
"    <li>",
"     Green N, Van Zeeland N. Fractures and dislocations about the elbow. In: Skeletal Trauma in Children, 4th edition, Green N, Swiontowski.  (Eds), Elsevier, Philadelphia 2008. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/20\">",
"      Keppler P, Salem K, Schwarting B, Kinzl L. The effectiveness of physiotherapy after operative treatment of supracondylar humeral fractures in children. J Pediatr Orthop 2005; 25:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/21\">",
"      Omid R, Choi PD, Skaggs DL. Supracondylar humeral fractures in children. J Bone Joint Surg Am 2008; 90:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/22\">",
"      Griffin KJ, Walsh SR, Markar S, et al. The pink pulseless hand: a review of the literature regarding management of vascular complications of supracondylar humeral fractures in children. Eur J Vasc Endovasc Surg 2008; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/23\">",
"      Mangat KS, Martin AG, Bache CE. The 'pulseless pink' hand after supracondylar fracture of the humerus in children: the predictive value of nerve palsy. J Bone Joint Surg Br 2009; 91:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/24\">",
"      Blakey CM, Biant LC, Birch R. Ischaemia and the pink, pulseless hand complicating supracondylar fractures of the humerus in childhood: long-term follow-up. J Bone Joint Surg Br 2009; 91:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/25\">",
"      Lyons ST, Quinn M, Stanitski CL. Neurovascular injuries in type III humeral supracondylar fractures in children. Clin Orthop Relat Res 2000; :62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/26\">",
"      Jones ET, Louis DS. Median nerve injuries associated with supracondylar fractures of the humerus in children. Clin Orthop Relat Res 1980; :181.",
"     </a>",
"    </li>",
"    <li>",
"     Price C, Phillips J, Devito D. Management of fractures. In: Lovell &amp;  Winter's Pediatric Orthopaedics, 5th, Morrissey, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.1319.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/28\">",
"      Abe M, Ishizu T, Shirai H, et al. Tardy ulnar nerve palsy caused by cubitus varus deformity. J Hand Surg Am 1995; 20:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/29\">",
"      Gogola GR. Pediatric humeral condyle fractures. Hand Clin 2006; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25961/abstract/30\">",
"      Mazda K, Boggione C, Fitoussi F, Penne&ccedil;ot GF. Systematic pinning of displaced extension-type supracondylar fractures of the humerus in children. A prospective study of 116 consecutive patients. J Bone Joint Surg Br 2001; 83:888.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6539 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-EF0408A01F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25961=[""].join("\n");
var outline_f25_22_25961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Soft tissue structures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Vascular anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurovascular examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pulse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Neurologic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RADIOGRAPHIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radiologic technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radiographic views",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Supracondylar fracture classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Associated fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Absent pulse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Acute compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Analgesia and immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Orthopedic consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DEFINITIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Type I fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Type II fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Type III fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Vascular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Volkmann ischemic contracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Neurologic deficit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Cubitus varus deformity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6539|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/53/11088\" title=\"diagnostic image 1\">",
"      Supracondylar fracture line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/2/23586\" title=\"diagnostic image 2\">",
"      Normal AP and lateral elbow radiograph child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/4/29760\" title=\"diagnostic image 3\">",
"      Normal lateral elbow radiograph child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/16/23823\" title=\"diagnostic image 4\">",
"      Type I supracondylar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/53/32607\" title=\"diagnostic image 5\">",
"      Type II supracondylar fracture 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/61/12240\" title=\"diagnostic image 6\">",
"      Type II supracondylar fracture 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/0/18432\" title=\"diagnostic image 7\">",
"      Type III supracondylar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/55/24432\" title=\"diagnostic image 8\">",
"      Occult supracondylar and radius fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6539|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/25/30111\" title=\"figure 1\">",
"      Supracondylar anatomy child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/60/4036\" title=\"figure 2\">",
"      Supracondylar extension fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/52/23365\" title=\"figure 3\">",
"      Major arteries and nerves of the anterior elbow region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/35/44593\" title=\"figure 4\">",
"      Supracondylar fracture neurovascular impingement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/56/20354\" title=\"figure 5\">",
"      Brachial artery tethering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/15/34034\" title=\"figure 6\">",
"      Supracondylar flexion fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/60/16321\" title=\"figure 7\">",
"      S shape supracondylar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/49/35600\" title=\"figure 8\">",
"      Supracondylar fracture with pucker sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/56/24463\" title=\"figure 9\">",
"      Ulnar nerve test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/7/14463\" title=\"figure 10\">",
"      Thumbs up sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/33/21009\" title=\"figure 11\">",
"      Elbow radiograph position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/15/22769\" title=\"figure 12\">",
"      Closed reduction of a supracondylar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/52/18255\" title=\"figure 13\">",
"      Cubitus varus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6539|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/33/26142\" title=\"picture 1\">",
"      OK sign to assess median nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6539|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/11/24763\" title=\"table 1\">",
"      Elbow sensation strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/31/28155\" title=\"table 2\">",
"      Radiographic views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19607?source=related_link\">",
"      Elbow anatomy and radiographic diagnosis of elbow fracture in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=related_link\">",
"      Epicondylar and transphyseal elbow fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19175?source=related_link\">",
"      Evaluation and management of condylar elbow fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/35/20018?source=related_link\">",
"      Patient information: Elbow fracture in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_22_25962="Assessment and management of the acutely agitated or violent adult";
var content_f25_22_25962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment and management of the acutely agitated or violent adult",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25962/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25962/contributors\">",
"     Gregory Moore, MD, JD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25962/contributors\">",
"     James A Pfaff, MD, FACEP, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25962/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/22/25962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/22/25962/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/22/25962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient violence occurs in many clinical settings and clinicians must be prepared to cope effectively with agitated patients in order to reduce the risk of serious injury to the patient and caretakers. The significant illness, prolonged waiting times, and confusion often found in busy emergency departments (ED) creates a stressful atmosphere that can exacerbate feelings of agitation among patients and their families. The ED's 24-hour open door policy, availability of potential hostages, and widespread accessibility of drugs and weapons compound the problem.",
"   </p>",
"   <p>",
"    The evaluation and management of the acutely agitated or violent patient will be reviewed here. The management of specific psychiatric ailments and intoxicated or poisoned patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=see_link\">",
"     \"Evaluation of abnormal behavior in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=see_link\">",
"     \"Ethanol intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 50 percent of healthcare providers are victims of violence sometime during their careers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A 2008 survey of over 3500 United States (US) emergency department (ED) clinicians at 65 sites reported that 3461 physical attacks occurred over a five-year period and that guns or knives were brought to the ED on a daily or weekly basis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/3\">",
"     3",
"    </a>",
"    ]. Another survey of 263 emergency medicine residents and attending physicians found that 78 percent of participants experienced a violent workplace act in the prior year, distributed equally between males and females [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/4\">",
"     4",
"    </a>",
"    ]. Smaller surveys in the US have found comparable rates of verbal and physical violence directed against ED clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The problem of violence is not limited to the US or to EDs. Surveys of emergency care workers and nurses in Turkey and Australia report similar rates of violence as those in US studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A 1997 survey of psychiatry residents revealed that 73 percent reported being threatened, and 36 percent had been physically assaulted in residency. Two-thirds of them had received either no or inadequate training in managing combative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 4 to 8 percent of patients who present to psychiatric emergency departments (ED) are armed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. At one large urban county hospital ED in the US, an average of 5.4 weapons was confiscated each day using metal detector screening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/12\">",
"     12",
"    </a>",
"    ]. At this center, 26.7 percent of major trauma patients seen in the ED over a 14-year period were armed with lethal weapons (84 percent knives and 16 percent guns). The presence of weapons among many ED patients increases the potential for rapid escalation of violence. Unfortunately, predicting weapons carriage in any particular patient is not easy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of violent behavior is not well understood. A wide range of factors may play a role, including the environment, a patient's social and medical history, interpersonal relations, genetics, neurochemistry and endocrine function, and substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to assess for potentially dangerous organic causes of agitation as soon as this can be done safely (",
"    <a class=\"graphic graphic_table graphicRef82146 \" href=\"UTD.htm?36/46/37611\">",
"     table 1",
"    </a>",
"    ). In the emergency department, drug and alcohol intoxication or withdrawal are the most common diagnoses in combative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A rapid serum glucose measurement (eg, fingerstick glucose), pulse oximetry, and a complete set of vital signs should be obtained in all patients. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Post-restraint medical evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Known psychiatric illness is a risk factor for violent behavior, with schizophrenia (paranoid and nonparanoid), personality disorders, mania, and psychotic depression most often associated with violence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/16,18-20\">",
"     16,18-20",
"    </a>",
"    ]. Psychosis, delirium, or dementia may lead to violent behavior.",
"   </p>",
"   <p>",
"    The mnemonic FIND ME (functional [ie, psychiatric], infectious, neurologic, drugs, metabolic, endocrine) may be helpful to organize a diagnostic search for the etiology of delirium and violence (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VIOLENCE PREVENTION IN THE EMERGENCY DEPARTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are largely under-protected and under-prepared to prevent and manage violent patients. A telephone survey of 250 US hospitals with emergency departments (ED) revealed that approximately 23 percent of hospitals have a 24-hour security presence, 14 percent have security present part of the day, and 63 percent do not have security formally assigned to the ED at any time during the day [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/21\">",
"     21",
"    </a>",
"    ]. Only 21 percent control access to the ED during high-risk hours, 39 percent use a security code, 46 percent have alarm buttons, 14 percent have a seclusion room, 36 percent use closed circuit surveillance, and 1.6 percent use metal detectors. Security measures have increased in parallel with the rising ED census [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention of violence is best accomplished by developing a system that includes ongoing staff education, adequate personnel, and a well-designed physical structure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High-risk environments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive approach is needed to reduce violence at high-risk sites. One large urban US hospital with a high incidence of violent behavior reported no incident of weapons related violence or injury in the ED following implementation of the following measures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/12,22\">",
"     12,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large security force",
"     </li>",
"     <li>",
"      Metal detectors",
"     </li>",
"     <li>",
"      Bulletproof Plexiglas in triage areas",
"     </li>",
"     <li>",
"      Keypad security entry system",
"     </li>",
"     <li>",
"      Monitoring entry into the ED",
"     </li>",
"     <li>",
"      Strong barriers to prevent cars from driving into the department.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General prevention measures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Security personnel &ndash; A well-trained and responsive security force is a key element of any security system. Nevertheless, security personnel constitute a significant expense and their services are often curtailed or eliminated when hospitals face fiscal difficulties. The use of guns by hospital security personnel is controversial. Guards may be allowed to carry guns after completing extensive weapons training. Other devices, such as electric stun guns and pepper spray, represent less lethal alternatives but are not free of risk.",
"     </li>",
"     <li>",
"      Alarm systems &ndash; Alarm systems are commonly used in the ED and psychiatric wards. The goal of any alarm system is to obtain rapid assistance. False alarms must be minimized. A tiered alarm system is usually best. Panic buttons in each room activate a central buzzer in the ED. Several designated ED personnel respond initially and judge the level of response needed. Every ED should have at least one telephone with a direct line to police or security in case additional personnel are needed. A verbal code (eg, \"Dr. Armstrong to Room 9\") to call for additional help is useful [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limiting access &ndash; Controlling access into the ED and hospital helps to prevent violence. This can be done by limiting the number of entrances, controlling entryways (eg, buzzer activated doors), and monitoring who enters. High-risk EDs should limit access to one or two entrances, especially during the evening hours. During nonvisiting hours, all entrances to the hospital other than the ED should be locked.",
"     </li>",
"     <li>",
"      Caretaker education &ndash; Regular, brief education sessions with clinicians, nurses, and ancillary staff to train them in the prevention and management of agitated and violent patients may reduce the incidence of violence and improve work satisfaction [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interview preparation and setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients must be disarmed before an interview. Metal detectors can be used to identify weapons before patients are allowed entry into the emergency department (ED). The routine practice of undressing all patients and placing them in a gown serves as a nonconfrontational way to search for weapons. Searches should be performed in a nondiscriminatory manner [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/26\">",
"     26",
"    </a>",
"    ]. A warning sign should be prominently displayed (eg, \"For the safety of patients and staff, individuals entering the ED may be screened for weapons\"). Almost all patients and families will cooperate with searches and may feel safer as a result [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The setting of the patient interview should be private but not isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Some EDs have seclusion rooms specifically intended for interviewing a potentially dangerous patient. Whenever a potentially aggressive or volatile patient is interviewed, security personnel should be nearby and the door left open to allow both intervention and escape by the clinician.",
"   </p>",
"   <p>",
"    The patient and interviewer may be seated roughly equidistant from the door, or the interviewer may sit between the patient and the door. The patient should NOT sit between the clinician and the exit, nor should the exit be blocked. Blocking the door poses a risk of harm to the clinician if the patient feels the need to escape.",
"   </p>",
"   <p>",
"    Ideally, two exits should be available and doors should swing outward. This facilitates escape but may increase the chance of injury to anyone standing outside the door. The clinician should have unrestricted access to the door and therefore should never sit behind a desk.",
"   </p>",
"   <p>",
"    The interview room should not contain heavy objects that may be thrown, such as ashtrays, or other potential weapons, such as electrical cords, scalpels, needles, or hot liquids. The clinician should have a mechanism for alerting others of danger, such as a panic button or a code word or phrase that instructs others to call for security (eg, \"I need Dr. Armstrong in here\"). Glasses, earrings, neckties, and necklaces should be removed. Personal accessories that may be used to harm the clinician, such as a scissors or pocketknives, should be removed. The clinician should be aware of any objects within the room or on the patient's body, such as pens, watches, or belts, that may be used as weapons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23,28\">",
"     23,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patient assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of potentially violent patients can be difficult. Male gender, a history of violence, and drug or alcohol abuse are associated with violence, but ethnicity, diagnosis, age, marital status, and education do not reliably identify such behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/18,29-32\">",
"     18,29-32",
"    </a>",
"    ]. Patients with a history of violent behavior are more likely to inflict serious injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation of the combative patient begins with risk assessment and attention to safety measures. Usually violence erupts after a period of mounting tension. The astute practitioner may identify verbal and nonverbal cues and seize the opportunity to defuse the situation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a typical scenario, the patient first becomes angry, then resists authority, and finally becomes confrontational. However, violent behavior may erupt without warning, especially when caused by medical illness or dementia. Clinicians should not feel overly confident in their ability to sense impending danger. As a whole, practitioners tend to be poor predictors of impending violence. Nevertheless, the clinician should pay attention to any \"gut feeling\" that a dangerous situation may be developing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"     23",
"    </a>",
"    ]. An uncomfortable or threatening feeling during an interview is ominous, and appropriate precautions should be taken without delay.",
"   </p>",
"   <p>",
"    In the ED, an obviously angry patient should always be considered potentially violent. Signs of impending violence include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Provocative behavior",
"     </li>",
"     <li>",
"      Angry demeanor",
"     </li>",
"     <li>",
"      Loud, aggressive speech",
"     </li>",
"     <li>",
"      Tense posturing (eg, gripping arm rails tightly, clenching fists)",
"     </li>",
"     <li>",
"      Frequently changing body position, pacing",
"     </li>",
"     <li>",
"      Aggressive acts (eg, pounding walls, throwing objects, hitting oneself)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Psychiatric texts emphasize the attitude of the patient's hands as an indicator of tension.",
"   </p>",
"   <p>",
"    The patient should be removed from contact with belligerent accomplices or other provocative patients to prevent escalation. A quiet area with a window enabling direct observation is optimal. Because increased waiting times correlate with violent behavior, the evaluation of these patients should be expedited to prevent any escalation of aggression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Often, the aura of preferential treatment will defuse patient anger. Ancillary staff often resist this concept and dogmatically insist that the patient wait. They must be educated on the importance of \"moving someone to the head of the line\" when dealing with potential violence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are agitated but cooperative may be amenable to verbal deescalation techniques. Actively violent patients and uncooperative, agitated patients, particularly those who exhibit signs of impending violence, require immediate restraint. Patients who obviously do not understand what is occurring, for psychiatric or other reasons, or are unable to communicate and are perceived by medical staff to be potentially violent should be restrained. Assume that all violent patients are armed until proven otherwise, especially those presenting with major trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Verbal techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients who present with agitation or violent behavior deserve the chance to calm down in response to verbal techniques before physical restraints or sedative medications are implemented. During initial interactions with the patient using the techniques described below, it will rapidly become clear to the clinician whether the patient will cooperate. This interaction also enables the clinician to assess the patient's mental status. If the patient remains resistant or violent or is incapable of interacting appropriately then restraint is necessary.",
"   </p>",
"   <p>",
"    Agitated but cooperative, nonviolent patients may be amenable to verbal deescalation techniques. The interviewer should adopt an honest and straightforward manner [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/38\">",
"     38",
"    </a>",
"    ]. Friendly gestures can be helpful. Offer a soft chair or something to eat or drink (not a hot liquid, which may be used as a weapon) to establish trust. Many patients will decompress at this point, as offering food or drink appeals to their most basic human needs and builds trust.",
"   </p>",
"   <p>",
"    A nonconfrontational, but attentive and receptive manner without conveying weakness or vulnerability is optimal. Some patients become angry because they feel they are not being taken seriously or treated with respect and their anger abates when these concerns are addressed.",
"   </p>",
"   <p>",
"    A calm and soothing tone of voice should be used. It is important to avoid direct eye contact or approaching the patient from behind or moving suddenly, and to stand at least one arm's length away [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, an agitated patient may be aware of their impulse control problem and may welcome limit-setting behavior by the clinician (eg, \"I can help you with your problem, but I cannot allow you to continue threatening me or the ED staff\") [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"     23",
"    </a>",
"    ]. It is difficult to predict which patients will respond to this limit-setting approach. Some patients may interpret such statements as confrontational and escalate their behavior, in which case restraint becomes necessary.",
"   </p>",
"   <p>",
"    A key mistake when interviewing an agitated or potentially violent patient is failing to address violence directly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/30,38\">",
"     30,38",
"    </a>",
"    ]. The patient should be asked relevant questions such as: \"Do you feel like hurting yourself or someone else?\" and \"Do you carry a gun?\" Stating the obvious (eg, \"You look angry\") may help the patient to begin sharing emotions. If the patient becomes more agitated, it is important to speak in a conciliatory manner and offer supportive statements to diffuse the situation, such as, \"You obviously have a lot of will power and are good at controlling yourself.\" An offer of medication or restraints may prevent further escalation and is often welcomed.",
"   </p>",
"   <p>",
"    Some techniques used in business to manage upset customers can be applied to agitated patients. Among these are the three Fs and the philosophy of yes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three Fs (feel, felt, found) approach provides a framework for responding to the patient's emotional needs: \"I understand how you could feel that way. Others in the same situation have felt that way, too. Most have found that (doing ____) can help\".",
"   </p>",
"   <p>",
"    The philosophy of yes encourages the clinician to respond to the patient affirmatively. Examples of initial clinician responses using this approach might include: \"Yes, as soon as\", \"Okay, but first we need to\", or \"I absolutely understand why you want that done, but in my experience there are better ways of getting what you need\".",
"   </p>",
"   <p>",
"    Some common approaches to the combative patient are counterproductive and can lead to escalation. Arguing, machismo, condescension, or commanding the patient to calm down can have disastrous consequences. Patients often interpret such approaches as a challenge to \"prove themselves.\" A threat to call security personnel also invites aggression.",
"   </p>",
"   <p>",
"    Other potential mistakes include criticizing or interrupting the patient, responding defensively or taking the patient's ire personally, and not clarifying what the patient wants before responding.",
"   </p>",
"   <p>",
"    Never lie to a patient (eg, \"I am sure you will be out of here in no time\" when this is not the case). Once the lie becomes apparent, the patient may take out frustrations violently upon an unsuspecting nurse or colleague who follows the interviewer.",
"   </p>",
"   <p>",
"    Take all threats seriously. It is especially important not to deny or downplay threatening behavior. To do so places the interviewer at increased risk of assault and injury. An example of this principle involves a psychiatrist who was killed after entering the waiting room with a patient he knew was potentially violent and armed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/30\">",
"     30",
"    </a>",
"    ]. He erroneously believed that the strength of the clinician-patient relationship ensured his safety.",
"   </p>",
"   <p>",
"    If verbal techniques are unsuccessful and escalation occurs, the clinician should excuse himself and summon help.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical restraints",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     When to apply restraints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical restraints can be used when, despite a professional and proper approach to the combative patient, verbal techniques are unsuccessful. The use of restraints can be humane and effective while facilitating diagnosis and treatment of the patient and preventing injury to the patient and medical staff [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Restraints are never to be applied for convenience or punishment, and should be removed as soon as possible, usually once adequate chemical sedation is achieved. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Chemical sedation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Indications for emergency seclusion and restraint include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Imminent harm to others",
"     </li>",
"     <li>",
"      Imminent harm to the patient",
"     </li>",
"     <li>",
"      Significant disruption of important treatment or damage to the environment",
"     </li>",
"     <li>",
"      Continuation of an effective, ongoing behavior treatment program",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician may find it helpful to classify patients into three categories. First, those with an organic disorder for whom restraints facilitate evaluation. Second, those with functional psychosis for whom verbal techniques are less effective and restraints facilitate administration of neuroleptics. Third, those with personality disorders for whom verbal techniques are not useful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23,43\">",
"     23,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seclusion may be used to decrease environmental stimulation and at the patient's request in some instances [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/44\">",
"     44",
"    </a>",
"    ]. In other circumstances, seclusion or restraint may be contraindicated. As examples, seclusion is unsuitable for any patient who is hemodynamically unstable, suicidal, self-abusive, self-mutilating, or has overdosed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/16,45\">",
"     16,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     How to apply restraints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restraints should be implemented systematically, ideally using an approved institutional protocol. This protocol begins with the examiner leaving the room once verbal techniques have been unsuccessful and summoning assistance. It may be helpful to consider the application of restraints like a procedure, analogous to running an advanced cardiac life support code [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The restraint team should have at least five people, including a team leader. The leader is the only person giving orders and should be the person with the most experience implementing restraints, whether a clinician, nurse, or security officer. Before entering the room, the leader outlines the restraint protocol and warns of anticipated danger (eg, the presence of objects that may be used as weapons). All team members should remove personal effects, which the patient could use against them. If the patient to be restrained is female, at least one member of the restraint team should be female to diminish potential allegations of sexual assault.",
"   </p>",
"   <p>",
"    The team enters the room in force and displays a professional, rather than threatening, attitude. Many violent individuals decompress at this point, as a show of force protects their ego (eg, \"I would have fought back but there were too many against me\"). The leader speaks to the patient in a calm and organized manner, explaining why restraints are needed and what the course of events will be (eg, \"You will receive a medical and psychiatric examination as well as treatment\"). The patient is instructed to cooperate and lie down to have restraints applied. Some patients will be relieved at the protection to self and others afforded by restraints when they feel themselves losing control. However, even if the patient suddenly appears less dangerous, physical restraints MUST be placed once the decision to use them has been made. Do NOT negotiate with the patient at this point.",
"   </p>",
"   <p>",
"    Some larger hospitals use a designated violence management team that responds to all patient encounters in which restraints may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/47\">",
"     47",
"    </a>",
"    ]. The basic approach to individual patients is similar to that described here, but all team members have expertise managing violent patients. The team may include a psychiatric nurse. This approach eliminates the difficulty of providing regular training for all hospital staff and helps to ensure a consistent, expert approach to potentially violent situations. At smaller institutions this approach may not be feasible.",
"   </p>",
"   <p>",
"    If it becomes necessary to use force to control the patient, one team member restrains a preassigned extremity by controlling the major joint (knee or elbow). This can be accomplished by locking the major joint in extension. The team leader controls the head. If the patient is armed with a makeshift weapon, two mattresses can be used to charge and immobilize or sandwich the patient. Restraints are applied securely to each extremity and tied to the solid frame of the bed (not side rails, as later repositioning of side rails also repositions the patient's extremity). To prevent lower extremities from flailing independently, it may be best to cross the legs at the ankle and then attach the restraint to the bed frame at the opposite side.",
"   </p>",
"   <p>",
"    Leather is the optimal material for restraints because it is strong, prevents escape, and is less constricting than typical soft restraints. Gauze should not be used. Soft restraints are helpful in restricting extremity use in a semi-cooperative patient, but are less effective in the truly violent patient who continues to struggle.",
"   </p>",
"   <p>",
"    If chest restraints are used, it is vital that adequate chest expansion for ventilation is ensured. Applying a soft Philadelphia collar to the patient's neck will help to prevent head-banging and biting. Whenever possible, the treating clinician should not participate directly in applying restraints in order to preserve the clinician-patient relationship and not be viewed as adversarial. Restraining patients on their side helps to prevent aspiration, although supine positioning with the head elevated is more comfortable for the patient and allows a more thorough medical examination while providing some protection against aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Once the patient is immobilized, announcing \"the crisis is over\" will have a calming effect on the restraint team and the patient.",
"   </p>",
"   <p>",
"    We recommend avoiding the prone restraint position and using aggressive chemical sedation in patients who continue to struggle against physical restraints. Sudden, unexpected deaths have been reported in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/48-53\">",
"     48-53",
"    </a>",
"    ]. Restraints applied by prehospital personnel that place patients in the prone or hobble position (ie, arms and legs restrained behind the patient) have resulted in deaths possibly due to asphyxia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/51\">",
"     51",
"    </a>",
"    ]. While healthy volunteers do not appear to experience asphyxia when exerting themselves against restraints, the combative patient often suffers from other conditions which increase risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Restrained patients who are intoxicated with cocaine, amphetamines, or other stimulants appear to be at particularly high risk for adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Increased sympathetic tone and altered pain sensation may allow exertion beyond normal physiologic limits in these patients and may cause vasoconstriction that impedes the clearance of metabolic waste products. Altered respiratory mechanics due to a restrained posture in an acidemic patient may impair respiratory compensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Monitoring patient and performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;After restraints have been applied successfully, the patient should be monitored frequently and have his position changed regularly to prevent neurovascular sequelae such as circulatory obstruction, pressure sores, and paresthesias, as well as to avoid rhabdomyolysis associated with continued combativeness. A standardized form is recommended for this monitoring and should be developed by every ED or ward that physically restrains patients. Documentation should include the specific indication for restraints and a colleague's agreement that restraints were necessary. Physical restraints should be removed as soon as possible.",
"   </p>",
"   <p>",
"    The restraint team should review their performance and discuss ways to improve effectiveness. Education and rehearsal by staff is imperative to maintain skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chemical sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical sedation may be necessary, with or without physical restraints, in a patient that does not respond to verbal deescalation techniques. Rapid tranquilization may be required in the agitated or violent patient. Anticipating the need for pharmacologic management early in the clinical course of a patient likely to become agitated may obviate the need for physical restraint.",
"   </p>",
"   <p>",
"    The ideal sedative medication for the agitated or violent patient would be rapidly acting, effective regardless of the route of administration, and possess minimal side effects. Few double-blinded, randomized, placebo-controlled trials have been performed to establish the efficacy or safety of any single medication in the management of acute delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/57\">",
"     57",
"    </a>",
"    ]. With all medications, the degree of sedation required must be balanced against potential side effects.",
"   </p>",
"   <p>",
"    The three major classes of medication generally used to control the violent or agitated patient include benzodiazepines, first generation (typical) antipsychotics, and second generation (atypical) antipsychotics. Each class is discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Patient-based approach to drug selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A treatment algorithm outlining our approach to chemical sedation of the acutely agitated patient, including specific medication suggestions, is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef61852 \" href=\"UTD.htm?8/59/9139\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In summary we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For severely violent patients requiring immediate sedation, give a rapidly acting first generation (typical) antipsychotic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      ) or benzodiazepine alone (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      ) or a combination of a first generation antipsychotic and a benzodiazepine (eg, droperidol and midazolam, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Combination therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with agitation from drug intoxication or withdrawal, give a benzodiazepine.",
"     </li>",
"     <li>",
"      For patients with undifferentiated agitation, we prefer benzodiazepines, but first generation antipsychotics are a reasonable choice.",
"     </li>",
"     <li>",
"      For agitated patients with a known psychiatric disorder, we prefer first generation antipsychotic agents, but second generation antipsychotics are a reasonable choice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One management principle is to move to a different class when the first is ineffective or excessive doses are required. Some patients may have paradoxical reactions and become more agitated after receiving a particular medication. In such cases, no additional agents from this class should be given and only alternative classes used.",
"   </p>",
"   <p>",
"    The use of injectable medications may be viewed as an assault by the patient, invoking images of punishment and incarceration rather than therapy and relief [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/58\">",
"     58",
"    </a>",
"    ]. For the agitated but nonviolent patient willing to cooperate with treatment, the use of oral medication may be as effective as a parenteral form [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006 the American College of Emergency Physicians published a clinical policy that discusses pharmacologic treatment for the acutely agitated patient in the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/60\">",
"     60",
"    </a>",
"    ]. These guidelines reflect common practice in many EDs throughout the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, we prefer benzodiazepines when sedating the patient with agitation from an unknown cause.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    are used most often.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      is commonly used due to its rapidity of action, effectiveness, short half-life, and intramuscular (IM) or intravenous (IV) route of administration [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. The usual dose is 0.5 to 2 mg IV or IM. Some experts give doses as frequently as every 10 minutes for severely agitated patients, although standard sources of drug information suggest a dosing interval of 30 minutes. The half-life of lorazepam is 10 to 20 hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      is an effective sedative with a more rapid onset than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      but a shorter duration of action (one to two hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/63\">",
"       63",
"      </a>",
"      ]. The usual dose is 2.5 to 5 mg IV or IM. In severely agitated patients, doses may be given every three to five minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benzodiazepines may cause respiratory depression, excessive somnolence, and less commonly, paradoxical disinhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/64\">",
"     64",
"    </a>",
"    ]. Clinicians must be vigilant about monitoring the respiratory function of patients receiving benzodiazepines. In agitated but cooperative patients, benzodiazepines may be given orally using the same doses described above.",
"   </p>",
"   <p>",
"    Benzodiazepines are especially useful in patients who are agitated from drug or alcohol intoxication or withdrawal, but retain efficacy in acute psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/18,65\">",
"     18,65",
"    </a>",
"    ]. Alcohol withdrawal and overdoses of particular drugs may require treatment with large cumulative doses. Benzodiazepines may be more effective than neuroleptics in reducing delirium and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/66\">",
"     66",
"    </a>",
"    ]. Benzodiazepines are also useful in patients at risk for seizure or when the anticholinergic side effects or akathisia associated with antipsychotics might prove harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of benzodiazepines in treating acute agitation has been demonstrated in several trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one double-blinded, randomized trial involving 153 acutely agitated patients in the emergency department (ED),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      (median dose 5 mg) was as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      (median dose 10 mg) in achieving sedation within ten minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/68\">",
"       68",
"      </a>",
"      ]. Three patients in the midazolam group temporarily required assisted ventilation and one was intubated.",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      (5 mg IM) achieved more rapid sedation but more often required additional medication for breakthrough symptoms compared with those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      (5 mg IM) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      (20 mg IM) in a double-blinded randomized trial involving 144 agitated ED patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another double-blinded, randomized trial performed in an urban ED,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      (5 mg IM) was found to provide more rapid sedation of severely agitated patients than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      (2 mg IM) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      (5 mg IM) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/70\">",
"       70",
"      </a>",
"      ]. All three agents provided effective sedation and no differences in hemodynamics or respiratory function was noted among the 111 patients involved.",
"     </li>",
"     <li>",
"      One unblinded, randomized trial involving 301 patients being treated in a psychiatric emergency department found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      to be more effective for rapid sedation (within 20 minutes) of agitated patients than either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"       promethazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one double-blinded randomized controlled trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      was as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      in reducing aggression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     First generation (typical) antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The older or \"typical\" antipsychotics include the butyrophenones and phenothiazines. Among the multiple medications in this class, the butyrophenones",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    are used most often to manage acute agitation. The mechanisms and general clinical use of these agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      has been used effectively for many years to control violent and agitated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. It can be given IV, IM, or orally, although its IV use is not approved by the United States Food and Drug Administration (FDA). It is usually given in doses of 2.5 to 10 mg. The onset of action is within 30 to 60 minutes. The dose should be decreased by one half in the elderly. Some clinicians give repeat doses as frequently as every 15 to 20 minutes in patients with severe agitation until the desired level of sedation is achieved, but according to the manufacturer doses may be repeated every 30 minutes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       Droperidol",
"      </a>",
"      is an analog of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      with a shorter half-life. It can be given IM or IV and is usually given in doses of 2.5 to 5 mg. Its onset of action ranges from 15 to 30 minutes, with a duration of six to eight hours [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/75\">",
"       75",
"      </a>",
"      ]. Several randomized trials have demonstrated the effectiveness of droperidol in controlling acute agitation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/62,68,69,75-77\">",
"       62,68,69,75-77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All first generation antipsychotics possess quinidine-like cardiac effects resulting in QT prolongation, with the potential for causing dysrhythmias, particularly torsades de pointes. In 2001,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    was given a \"black box\" warning by the United States Food and Drug Administration (FDA) because of the risk of QT prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/78\">",
"     78",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    received a similar warning from the FDA in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These warnings have generated substantial debate, given the drugs' long history of effectiveness and the dearth of substantial clinical evidence demonstrating harm [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. In one retrospective review of 2468 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    in the ED, only six serious adverse events were identified, including a single cardiac arrest in a patient with a normal QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe both drugs are effective first-line agents for the sedation of violent and acutely agitated patients. They should be used with caution in those at risk for QT prolongation, such as patients taking other medications known to prolong the QT interval, patients likely to have electrolyte disorders (eg, hypokalemia and hypomagnesemia), and patients with congenital conditions associated with QT prolongation. If feasible, an electrocardiogram (ECG) should be performed prior to administration, but this may be impossible when managing a violent patient. In such cases, an ECG should be obtained once the patient is sufficiently sedated.",
"   </p>",
"   <p>",
"    Neuroleptics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    , should be avoided in cases of alcohol withdrawal, benzodiazepine withdrawal, other withdrawal syndromes, anticholinergic toxicity, and patients with seizures. If possible, these medications should also be avoided in pregnant and lactating females and phencyclidine overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"     23",
"    </a>",
"    ]. First generation antipsychotics can cause extrapyramidal side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H423924693\">",
"    <span class=\"h3\">",
"     Second generation (atypical) antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newer or \"atypical\" antipsychotics reportedly cause fewer extrapyramidal side effects and less sedation than first generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. The second generation antipsychotics used most often in the acute setting include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    . The mechanisms and general clinical use of these agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience using second generation antipsychotic medications to control severe acute agitation in the emergency department (ED) is limited. Preliminary studies suggest the second generation antipsychotics can effectively control acute agitation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/69,85\">",
"     69,85",
"    </a>",
"    ]. We prefer to use benzodiazepines and first generation antipsychotics, as described above, pending the completion of rigorous trials in undifferentiated ED patient populations. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Patient-based approach to drug selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    is available in intramuscular (IM) and oral formulations for agitation associated with bipolar mania and schizophrenia. IM olanzapine is given in an initial dose of 10 mg and has an onset of action of 15 to 45 minutes and a half-life of two to four hours. Olanzapine in a dose of 10 mg IM appears not to cause excessive sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     Risperidone",
"    </a>",
"    is generally used for schizophrenia and data for its use in acute agitation are limited. It has been useful in controlling agitation in the elderly and may have similar effects to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    when a benzodiazepine is added [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/87\">",
"     87",
"    </a>",
"    ]. It is only available in an oral and IM depot form and the usual dose is 1 to 2 mg. The time to peak concentration is shorter than some other oral second generation antipsychotics. Risperidone is preferred when rapid control of agitation is needed and an oral medication is to be given [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     Ziprasidone",
"    </a>",
"    has been used to treat agitated schizophrenic and bipolar patients, and is available in oral and IM formulations. It is typically given in an IM dose of 10 to 20 mg IM and has on onset of action of 15 to 20 minutes and a half-life of two to four hours. Many psychiatric emergency services in the US use a 20 mg IM dose of ziprasidone as first line treatment for severe agitation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second generation antipsychotics cause some degree of QT prolongation, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    most likely to cause this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/89\">",
"     89",
"    </a>",
"    ]. Precautions similar to those suggested for first generation antipsychotics should be used. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'First generation (typical) antipsychotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines and first generation antipsychotics can be used together to sedate combative patients. As examples, the following combinations have been shown to be effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      (5 mg IV or IM) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      (5 mg IV or IM)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      (2 mg IV or IM) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      (5 mg IV or IM)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These combinations achieve more rapid sedation than either drug alone and may reduce side effects. Half doses should be used in the elderly. If additional medication is needed, a reasonable approach to titration is to give additional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    every 3 to 5 minutes or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    every 10 to 20 minutes as needed.",
"   </p>",
"   <p>",
"    The use of combination therapy is supported by a small number of randomized trials performed in emergency departments and psychiatric wards [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/64,90,91\">",
"     64,90,91",
"    </a>",
"    ]. In a multicenter, randomized, double-blind controlled trial, the combination of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    (5 mg IV) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    (5 mg IV) and midazolam provided more rapid sedation of acutely agitated emergency department patients (n=336) than midazolam alone (2.5 to 5 mg IV used for all three groups) without an increase in adverse events and with less need for rescue medication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/91\">",
"     91",
"    </a>",
"    ]. The mean times to sedation were 21.3 minutes for the droperidol group, 14 minutes for the olanzapine group, and 67.8 minutes for the midazolam only (ie, control) group. Further study of intravenous administration of olanzapine and other second generation antipsychotics is needed before such use can be widely recommended for the treatment of acute agitation.",
"   </p>",
"   <p>",
"    Smaller randomized trials have found the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    to be more effective than either drug alone in sedating acutely agitated or psychotic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/64,90\">",
"     64,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Post-restraint medical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient is restrained, the clinician must investigate the cause of agitation and determine whether it is medical (ie, organic) or psychiatric (ie, functional). Patients over the age of 40 with new psychiatric symptoms are more likely to have an organic cause. Elderly patients are at higher risk for organic delirium due to medical illness or adverse reactions to medications. Patients with a history of drug or alcohol abuse may exhibit violent behavior as a manifestation of an intoxication or withdrawal syndrome. The acute onset of agitated behavior suggests an organic etiology. Most psychiatric patients are alert and oriented and have a history of psychiatric illness. The differentiation of medical from psychiatric disorders, the evaluation of delirium and confusional states, and the general assessment of drug overdose patients are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=see_link\">",
"     \"Evaluation of abnormal behavior in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few basic points concerning the medical evaluation bear emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The importance of obtaining a complete set of vital signs and performing a thorough mental status and neurologic examination cannot be overemphasized. Patient restraint may be necessary to accomplish even the most rudimentary physical inspection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"       \"The detailed neurologic examination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A rapid blood glucose determination and pulse oximetry should be obtained in all combative patients.",
"     </li>",
"     <li>",
"      Combative patients who are sedated and subsequently deteriorate frequently suffer from an unrecognized infection or drug overdose.",
"     </li>",
"     <li>",
"      Patients under 40 years of age, with a prior psychiatric history and a normal physical examination including vital signs, and who are oriented and regain a calm demeanor, likely require no further diagnostic testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Legal considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps no area of medicine is more fraught with legal considerations than care of the combative patient. Different laws apply according to the location. Regardless of the legal community in which a clinician practices, adherence to the following guidelines will help to minimize potential liability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be assessed by the clinician to determine if the patient appears to have the capacity to make reasonable decisions about their healthcare, workup, and therapy. Courts have consistently given great latitude to clinicians in retrospect as long as they were acting in good faith.",
"     </li>",
"     <li>",
"      Having a clinician coworker record that they agree with the assessment and treatment described by the clinician primarily responsible for the patient represents powerful supporting documentation. Although obtaining court approval in advance of actions is ideal, it is often impossible due to time constraints and the limited availability of legal authorities.",
"     </li>",
"     <li>",
"      If a clinician decides to suspend the liberty of a patient and make decisions for them, the reasons should be clearly documented in the medical chart and any required forms completed.",
"     </li>",
"     <li>",
"      When a clinician restrains a patient physically or sedates them chemically they become responsible for the well-being of the patient. Attention to adequate comfort, hydration, respiration, bathroom needs, and protection are required. Such a patient must be closely monitored.",
"     </li>",
"     <li>",
"      Should physical restraints be placed, they should be removed as soon as possible.",
"     </li>",
"     <li>",
"      A patient with the capacity to make reasonable decisions and who poses no threat to himself, the medical staff, or others cannot be confined or restrained without their permission. Doing so can lead to a legal charge of false imprisonment or battery. In the US, false imprisonment and battery are generally not covered in malpractice insurance policies.",
"     </li>",
"     <li>",
"      Duty to Warn is a legal concept, present in some locations, that requires a clinician to warn a person who is in danger from a combative patient. Failure to do so may make the clinician liable for injury to the third party.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, violent behavior unrelated to organic illness or drug intoxication or withdrawal should be followed by psychiatric consultation and evaluation. The medical record should reflect that the ED evaluation makes an acute medical condition unlikely to have caused or contributed to the patient's behavior. If the etiology of the patient's violent behavior is due to drug or alcohol intoxication, the patient should be observed until he has reached the point where a therapeutic interview can be conducted by the psychiatrist. Alternatively, the patient may be transported to a facility where he can be observed until the effects of the intoxicants have abated.",
"   </p>",
"   <p>",
"    Rather than pronouncing the patient \"medically clear\" the clinician should clearly convey his findings and recommendations directly to the consulting psychiatrist. After the violent patient has been medically evaluated, a decision must be made to begin commitment proceedings or discharge the patient. Admission is appropriate for violent patients who state specific intentions to hurt themselves or others, refuse to answer questions or cooperate, are under the influence of drugs or alcohol, are psychotic, or have an organic brain syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23,92\">",
"     23,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discharge may be appropriate if the violent behavior was caused by a temporary organic syndrome (eg, intoxication), medical and psychiatric evaluation reveals no other significant problem requiring acute intervention, and the patient is deemed in control and no longer violent. All discharged patients should be given specific follow-up evaluation and discharge instructions.",
"   </p>",
"   <p>",
"    If a violent patient escapes the ED, law enforcement authorities should be notified. If the patient threatened violence to a specific individual before escape, that individual should be notified as well. If the patient has committed a violent act, it is often possible to discharge the patient in police custody. Jail is a safe disposition as long as authorities are warned of potential danger. If the patient needs to be transferred, the accepting clinician should be warned of possible violence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DEFENSE AGAINST ASSAULT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, physical assault may occur despite appropriate precautions and interventions. If assaulted, immediately summon help, preferably by use of a panic button. Maintain a sideward posture, keeping the arms ready for self protection. If faced with a punch or a kick, deflect with an arm or a leg. If choking is attempted, tuck the chin in to protect the airway and carotid arteries. If bitten, do not pull away, but rather push toward the mouth and hold the nares shut to entice opening of the mouth.",
"   </p>",
"   <p>",
"    If threatened with a weapon, try to appear calm and comply with demands [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"     23",
"    </a>",
"    ]. Adopt a nonthreatening posture and avoid sudden movements. Do not attempt to reach for the weapon. Avoid argument, despair, or whining. If taken hostage, attempt to establish a human connection with the hostage taker, as a hostage taker will rarely murder someone if a relationship has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/19,26\">",
"     19,26",
"    </a>",
"    ]. Offering to administer to ill or injured hostages makes them appear less expendable. Do not bargain or make promises, and do not lie, as the consequences could be disastrous. Reassure the hostage taker that someone authorized to hear his complaints or demands should arrive promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/26\">",
"     26",
"    </a>",
"    ]. If a weapon is put down, do not reach for it but rather attempt to verbally resolve the crisis while awaiting security arrival. Call law enforcement authorities to provide a professional hostage negotiator if needed.",
"   </p>",
"   <p>",
"    Each hospital should have a plan of action in the case of extreme violence. The plan should include prevention and safety measures, a means for rapid notification of security and police personnel, evacuation plans, medical treatment, and crisis intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/12,26\">",
"     12,26",
"    </a>",
"    ]. A novel approach uses a trained violence management team to provide a mechanism for dealing with aggressive patients and to protect the staff [",
"    <a class=\"abstract\" href=\"UTD.htm?25/22/25962/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'How to apply restraints'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to 50 percent of healthcare providers are victims of violence sometime during their careers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the emergency department (ED), drug and alcohol intoxication or withdrawal are the most common causes of severe agitation. Fingerstick glucose, pulse oximetry, and a complete set of vital signs should be obtained in all combative patients. It is important to assess for potentially dangerous organic causes of agitation as soon as this can be done safely (",
"      <a class=\"graphic graphic_table graphicRef82146 \" href=\"UTD.htm?36/46/37611\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology and differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Post-restraint medical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians are largely under-protected and under-prepared to prevent and manage violent patients. A number of prevention measures are described in the text. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Violence prevention in the emergency department'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Basic safety measures should be followed during all interviews with potentially violent patients. All patients must be disarmed before an interview. The setting should be private but not isolated, and no obstacle should exist between the clinician and the exit. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Interview preparation and setting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Male gender, a history of violence, and drug or alcohol abuse are associated with violence. Signs of impending violence include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Provocative behavior",
"     </li>",
"     <li>",
"      Angry demeanor",
"     </li>",
"     <li>",
"      Loud, aggressive speech",
"     </li>",
"     <li>",
"      Tense posturing (eg, gripping arm rails tightly, clenching fists)",
"     </li>",
"     <li>",
"      Frequently changing body position, pacing",
"     </li>",
"     <li>",
"      Aggressive acts (eg, pounding walls, throwing objects, hitting oneself) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient assessment'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Actively violent patients and uncooperative, agitated patients, particularly those who exhibit signs of impending violence, require immediate restraint. Assume that all violent patients are armed until proven otherwise. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nearly all patients who present with agitation or violent behavior deserve the chance to calm down in response to verbal techniques. The following suggestions increase the likelihood of a successful interview:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adopt an honest and straightforward manner.",
"     </li>",
"     <li>",
"      Perform friendly gestures (eg, offer food).",
"     </li>",
"     <li>",
"      Avoid direct eye contact; do not approach the patient from behind or move suddenly; stand at least one arm's length away.",
"     </li>",
"     <li>",
"      Address violence directly: The patient should be asked relevant questions, such as, \"Do you feel like hurting yourself or someone else?\"",
"     </li>",
"     <li>",
"      Avoid arguing, machismo, condescension, or commanding the patient to calm down.",
"     </li>",
"     <li>",
"      Never lie to the patient.",
"     </li>",
"     <li>",
"      Take all threats seriously. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Verbal techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical restraints can be used when, despite a proper approach to the combative patient, verbal techniques are unsuccessful. The implementation of physical restraints is described in the text. Every restrained patient must be carefully and frequently monitored. Physical restraints should be removed as soon as possible. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical restraints'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid tranquilization may be required in the agitated or violent patient. A treatment algorithm outlining our approach to chemical sedation of the acutely agitated patient, including specific medication suggestions, is provided (",
"      <a class=\"graphic graphic_algorithm graphicRef61852 \" href=\"UTD.htm?8/59/9139\">",
"       algorithm 1",
"      </a>",
"      ). In summary, we suggest the following approach for the chemical sedation of acutely agitated or violent patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For severely violent patients requiring immediate sedation, we suggest treatment with a rapidly acting first generation (typical) antipsychotic alone (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      ), a rapidly acting benzodiazepine alone (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      ), or a combination of a first generation antipsychotic and a benzodiazepine (eg, midazolam and droperidol, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with agitation from drug intoxication or withdrawal, we suggest treatment with a benzodiazepine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with undifferentiated agitation, we suggest treatment with benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). First generation antipsychotics are also a reasonable choice.",
"     </li>",
"     <li>",
"      For agitated patients with a known psychiatric disorder, we suggest treatment with first generation antipsychotic agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Second generation antipsychotics are also a reasonable choice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6423320\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/1\">",
"      Schulte JM, Nolt BJ, Williams RL, et al. Violence and threats of violence experienced by public health field-workers. JAMA 1998; 280:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/2\">",
"      Al-Sahlawi KS, Zahid MA, Shahid AA, et al. Violence against doctors: 1. A study of violence against doctors in accident and emergency departments. Eur J Emerg Med 1999; 6:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/3\">",
"      Kansagra SM, Rao SR, Sullivan AF, et al. A survey of workplace violence across 65 U.S. emergency departments. Acad Emerg Med 2008; 15:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/4\">",
"      Behnam M, Tillotson RD, Davis SM, Hobbs GR. Violence in the emergency department: a national survey of emergency medicine residents and attending physicians. J Emerg Med 2011; 40:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/5\">",
"      Gates DM, Ross CS, McQueen L. Violence against emergency department workers. J Emerg Med 2006; 31:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/6\">",
"      Li SF, Grant K, Bhoj T, et al. Resident experience of abuse and harassment in emergency medicine: ten years later. J Emerg Med 2010; 38:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/7\">",
"      Boz B, Acar K, Ergin A, et al. Violence toward health care workers in emergency departments in Denizli, Turkey. Adv Ther 2006; 23:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/8\">",
"      Crilly J, Chaboyer W, Creedy D. Violence towards emergency department nurses by patients. Accid Emerg Nurs 2004; 12:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/9\">",
"      Schwartz TL, Park TL. Assaults by patients on psychiatric residents: a survey and training recommendations. Psychiatr Serv 1999; 50:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/10\">",
"      NcNiel DE, Binder RL. Patients who bring weapons to the psychiatric emergency room. J Clin Psychiatry 1987; 48:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/11\">",
"      McCulloch LE, McNiel DE, Binder RL, Hatcher C. Effects of a weapon screening procedure in a psychiatric emergency room. Hosp Community Psychiatry 1986; 37:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/12\">",
"      Ordog GJ, Wasserberger J, Ordog C, et al. Weapon carriage among major trauma victims in the emergency department. Acad Emerg Med 1995; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/13\">",
"      Anderson AA, Ghali AY, Bansil RK. Weapon carrying among patients in a psychiatric emergency room. Hosp Community Psychiatry 1989; 40:845.",
"     </a>",
"    </li>",
"    <li>",
"     Tardiff K. Diagnosis and management of violent patients. In: Psychiatry, Michels R, Cavenar JD, Cooper AM, et al.  (Eds), Lippincott-Raven, Philadelphia 1997. Vol 3, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/15\">",
"      Volavka J. The neurobiology of violence: an update. J Neuropsychiatry Clin Neurosci 1999; 11:307.",
"     </a>",
"    </li>",
"    <li>",
"     Dubin WR, Weiss KJ. Emergency psychiatry. In: Psychiatry, Michels R, Cavenar JD, Cooper AM, et al.  (Eds), Lippincott-Raven, Philadelphia 1997. Vol 2, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/17\">",
"      Lavoie FW. Consent, involuntary treatment, and the use of force in an urban emergency department. Ann Emerg Med 1992; 21:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/18\">",
"      Citrome L, Volavka J. Violent patients in the emergency setting. Psychiatr Clin North Am 1999; 22:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/19\">",
"      Tardiff K. The current state of psychiatry in the treatment of violent patients. Arch Gen Psychiatry 1992; 49:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/20\">",
"      Tardiff K. Unusual diagnoses among violent patients. Psychiatr Clin North Am 1998; 21:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/21\">",
"      Ellis GL, Dehart DA, Black C, et al. ED security: a national telephone survey. Am J Emerg Med 1994; 12:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/22\">",
"      Preventing workplace violence: Tips for safety in emergency departments and psychiatric hospitals. Environment of Care News, published by Joint Commission Resources 2008; 11:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/23\">",
"      Rice MM, Moore GP. Management of the violent patient. Therapeutic and legal considerations. Emerg Med Clin North Am 1991; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/24\">",
"      Deans C. The effectiveness of a training program for emergency department nurses in managing violent situations. Aust J Adv Nurs 2004; 21:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/25\">",
"      Phillips S. Countering workplace aggression: an urban tertiary care institutional exemplar. Nurs Adm Q 2007; 31:209.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Emergency Physicians. Emergency department violence: prevention and management. Dallas 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/27\">",
"      Mattox EA, Wright SW, Bracikowski AC. Metal detectors in the pediatric emergency department: patron attitudes and national prevalence. Pediatr Emerg Care 2000; 16:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/28\">",
"      Kuhn W. Violence in the emergency department. Managing aggressive patients in a high-stress environment. Postgrad Med 1999; 105:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/29\">",
"      Cherry D, Annest JL, Mercy JA, et al. Trends in nonfatal and fatal firearm-related injury rates in the United States, 1985-1995. Ann Emerg Med 1998; 32:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/30\">",
"      Dubin WR, Wilson SJ, Mercer C. Assaults against psychiatrists in outpatient settings. J Clin Psychiatry 1988; 49:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/31\">",
"      Beech DJ, Mercadel R. Correlation of alcohol intoxication with life-threatening assaults. J Natl Med Assoc 1998; 90:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/32\">",
"      Scott KD, Schafer J, Greenfield TK. The role of alcohol in physical assault perpetration and victimization. J Stud Alcohol 1999; 60:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/33\">",
"      Owen C, Tarantello C, Jones M, Tennant C. Repetitively violent patients in psychiatric units. Psychiatr Serv 1998; 49:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/34\">",
"      Convit A, Isay D, Otis D, Volavka J. Characteristics of repeatedly assaultive psychiatric inpatients. Hosp Community Psychiatry 1990; 41:1112.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Occupational Safety and Health. Violence: Occupational Hazards in Hospitals. www.cdc.gov/niosh/topics/healthcare/#violence (Accessed on October 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/36\">",
"      Lavoie FW, Carter GL, Danzl DF, Berg RL. Emergency department violence in United States teaching hospitals. Ann Emerg Med 1988; 17:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/37\">",
"      McAneney CM, Shaw KN. Violence in the pediatric emergency department. Ann Emerg Med 1994; 23:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/38\">",
"      Hill S, Petit J. The violent patient. Emerg Med Clin North Am 2000; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     Morgan R. Calming Upset Customers: Staying Effective During Unpleasant Situations, 3rd, Crisp Learning, Canada 2002.",
"    </li>",
"    <li>",
"     Tardiff K. Adult antisocial behavior and criminality. In: Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry, 7th, Sadock BJ, Sadock VA.  (Eds), Lippincott Willaims &amp; Wilkins, Philadelphia 2000. Vol 2, p.1908.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/41\">",
"      Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000; 61 Suppl 14:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/42\">",
"      Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005; 11 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     Fauman B. Other psychiatric emergencies. In: Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry, 7th, Sadock BJ, Sadock VA.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. Vol 2, p.2040.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/44\">",
"      Huf G, Coutinho ES, Adams CE, TREC-SAVE Collaborative Group. Physical restraints versus seclusion room for management of people with acute aggression or agitation due to psychotic illness (TREC-SAVE): a randomized trial. Psychol Med 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/45\">",
"      Wynn R. Medicate, restrain or seclude? Strategies for dealing with violent and threatening behaviour in a Norwegian university psychiatric hospital. Scand J Caring Sci 2002; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/46\">",
"      Petit JR. Management of the acutely violent patient. Psychiatr Clin North Am 2005; 28:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/47\">",
"      Brayley J, Lange R, Baggoley C, et al. The violence management team. An approach to aggressive behaviour in a general hospital. Med J Aust 1994; 161:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/48\">",
"      Grant JR, Southall PE, Fowler DR, et al. Death in custody: a historical analysis. J Forensic Sci 2007; 52:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/49\">",
"      Stratton SJ, Rogers C, Brickett K, Gruzinski G. Factors associated with sudden death of individuals requiring restraint for excited delirium. Am J Emerg Med 2001; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/50\">",
"      Hick JL, Smith SW, Lynch MT. Metabolic acidosis in restraint-associated cardiac arrest: a case series. Acad Emerg Med 1999; 6:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/51\">",
"      Reay DT, Fligner CL, Stilwell AD, Arnold J. Positional asphyxia during law enforcement transport. Am J Forensic Med Pathol 1992; 13:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/52\">",
"      Pollanen MS, Chiasson DA, Cairns JT, Young JG. Unexpected death related to restraint for excited delirium: a retrospective study of deaths in police custody and in the community. CMAJ 1998; 158:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/53\">",
"      Otahbachi M, Cevik C, Bagdure S, Nugent K. Excited delirium, restraints, and unexpected death: a review of pathogenesis. Am J Forensic Med Pathol 2010; 31:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/54\">",
"      Michalewicz BA, Chan TC, Vilke GM, et al. Ventilatory and metabolic demands during aggressive physical restraint in healthy adults. J Forensic Sci 2007; 52:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/55\">",
"      Chan TC, Neuman T, Clausen J, et al. Weight force during prone restraint and respiratory function. Am J Forensic Med Pathol 2004; 25:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/56\">",
"      Chan TC, Vilke GM, Neuman T, Clausen JL. Restraint position and positional asphyxia. Ann Emerg Med 1997; 30:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/57\">",
"      Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry 2007; 68:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/58\">",
"      Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry 1999; 33:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/59\">",
"      Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003; 20:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/60\">",
"      Lukens TW, Wolf SJ, Edlow JA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med 2006; 47:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/61\">",
"      Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/62\">",
"      Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther 2010; 32:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/63\">",
"      Mendoza R, Djenderedjian AH, Adams J, Ananth J. Midazolam in acute psychotic patients with hyperarousal. J Clin Psychiatry 1987; 48:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/64\">",
"      Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/65\">",
"      Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/66\">",
"      Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 2004; 164:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/67\">",
"      Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry 1999; 156:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/68\">",
"      Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med 2006; 47:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/69\">",
"      Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med 2005; 12:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/70\">",
"      Nobay F, Simon BC, Levitt MA, Dresden GM. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med 2004; 11:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/71\">",
"      TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003; 327:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/72\">",
"      Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/73\">",
"      Clinton JE, Sterner S, Stelmachers Z, Ruiz E. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 1987; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/74\">",
"      Stotsky BA. Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Dis Nerv Syst 1977; 38:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/75\">",
"      Thomas H Jr, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 1992; 21:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/76\">",
"      Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med 1998; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/77\">",
"      Isbister GK, Calver LA, Page CB, et al. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med 2010; 56:392.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. www.fda.gov/medwatch/SAFETY/2001/inapsine.htm (Accessed on October 07, 2008).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Information for healthcare professionals: Haloperidol. www.fda.gov/Cder/drug/InfoSheets/HCP/haloperidol.htm (Accessed on October 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/80\">",
"      Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003; 41:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/81\">",
"      Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med 2002; 9:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/82\">",
"      Shale JH, Shale CM, Mastin WD. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. J Clin Psychiatry 2003; 64:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/83\">",
"      Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med 2005; 23:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/84\">",
"      Allen, MH, Currier, GW, Carpenter, D, et al. J Psychiatry Pract 2005; 11 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/85\">",
"      Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/86\">",
"      Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003; 21:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/87\">",
"      Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/88\">",
"      Rund DA, Ewing JD, Mitzel K, Votolato N. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. J Emerg Med 2006; 31:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/89\">",
"      Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/90\">",
"      Bieniek SA, Ownby RL, Penalver A, Dominguez RA. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/22/25962/abstract/91\">",
"      Chan EW, Taylor DM, Knott JC, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med 2013; 61:72.",
"     </a>",
"    </li>",
"    <li>",
"     Dubin WR, Weiss KJ. Emergency psychiatry. In: Psychiatry, Michels R, Cavenar JD, Cooper AM.  (Eds), Lippincott-Raven, Philadelphia 1997. Vol 2, p.1.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 291 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25962=[""].join("\n");
var outline_f25_22_25962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VIOLENCE PREVENTION IN THE EMERGENCY DEPARTMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High-risk environments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General prevention measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interview preparation and setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patient assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Verbal techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical restraints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - When to apply restraints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - How to apply restraints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Monitoring patient and performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chemical sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Patient-based approach to drug selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - First generation (typical) antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H423924693\">",
"      - Second generation (atypical) antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Post-restraint medical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Legal considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DEFENSE AGAINST ASSAULT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6423320\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/291|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/59/9139\" title=\"algorithm 1\">",
"      Management algorithm for violent patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/46/37611\" title=\"table 1\">",
"      Common causes violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/43/3773\" title=\"table 2\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=related_link\">",
"      Ethanol intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=related_link\">",
"      Evaluation of abnormal behavior in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_22_25963="Causes of INO";
var content_f25_22_25963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=22\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=22\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible etiologies of internuclear ophthalmoplegia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Multiple sclerosis (commonly bilateral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brainstem infarction (commonly unilateral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brainstem and fourth ventricle tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arnold-Chiari malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection: bacterial, viral, and other forms of meningioencephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocephalus, subdural hematoma, supratentorial arteriovenous malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional disorders: Wernickes's encephalopathy and pernicious anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic disorders: hepatic encephalopathy, maple syrup urine disease, abetalipoproteinemia, Fabry's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug intoxications: tricyclic antidepressants, phenothiazines, narcotics, lithium, barbiturates, propranolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Degenerative conditions: progressive supranuclear palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudointernuclear ophthalmoplegia of myasthenia gravis and Fisher's  syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25963=[""].join("\n");
var outline_f25_22_25963=null;
var title_f25_22_25964="Spectrum of immune compromise";
var content_f25_22_25964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of immune compromise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Significantly immunocompromising conditions include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematopoietic stem cell transplant (HCT) within the past two years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solid organ transplant (SOT) within the past year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment for rejection after SOT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active leukemia or lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aplastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft versus host disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent radiation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significantly immunosuppressive medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIDS with low CD4 count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Moderately immunocompromising conditions include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatic disease (cirrhosis and alcoholism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asplenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional deficiencies (depending on the nature of the deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minimally immunocompromising conditions include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy for leukemia/lymphoma or cancer more than&nbsp;three months earlier",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy in remission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High dose steroid use more than a month earlier",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild steroid use including inhaled, topical, intra-articular, bursal, or tendon injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV with &gt;500 CD4 lymphocytes/mm3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HCT recipients more than&nbsp;two years post-transplant who are not on immunosuppressive drugs and do not have graft versus host disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <ol>",
"      <li>",
"       Advising Travelers with Specific Needs: The Immunocompromised Traveler.",
"       <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-8-advising-travelers-with-specific-needs/immunocompromised-travelers.htm\">",
"        file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-8-advising-travelers-with-specific-needs/immunocompromised-travelers.htm",
"       </a>",
"       (Accessed on September 17, 2008).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25964=[""].join("\n");
var outline_f25_22_25964=null;
var title_f25_22_25965="ROS joint pain swell child";
var content_f25_22_25965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Review of systems in the differential diagnosis of childhood joint pain and swelling",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Affected system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manifestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"4\">",
"        Dermatologic",
"       </td>",
"       <td>",
"        SLE",
"       </td>",
"       <td>",
"        Malar rash and hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatomyositis",
"       </td>",
"       <td>",
"        Gottron's papules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic JIA",
"       </td>",
"       <td>",
"        Evanescent pink macular rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HSP",
"       </td>",
"       <td>",
"        Lower extremity purpuric lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"4\">",
"        Ophthalmologic",
"       </td>",
"       <td>",
"        Oligoarthritis or psoriatic JIA",
"       </td>",
"       <td>",
"        Asymptomatic chronic anterior uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enthesitis related arthritis",
"       </td>",
"       <td>",
"        Acute symptomatic uveitis (pain, redness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kawasaki disease",
"       </td>",
"       <td>",
"        Conjunctival injection without discharge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sjogren's syndrome",
"       </td>",
"       <td>",
"        Dry eyes with keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Oral",
"       </td>",
"       <td>",
"        SLE",
"       </td>",
"       <td>",
"        Painless oral ulcers on palate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behcet Disease",
"       </td>",
"       <td>",
"        Large extremely painful oral ulcers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"5\">",
"        Respiratory",
"       </td>",
"       <td>",
"        CF or immunodeficiency",
"       </td>",
"       <td>",
"        Recurrent pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"       <td>",
"        Destructive upper tract lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLE or systemic JIA",
"       </td>",
"       <td>",
"        Pleuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLE or scleroderma",
"       </td>",
"       <td>",
"        Interstitial lung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Churg-Strauss syndrome",
"       </td>",
"       <td>",
"        Eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"4\">",
"        Cardiovascular",
"       </td>",
"       <td>",
"        ARF or endocarditis",
"       </td>",
"       <td>",
"        New heart murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLE, systemic JIA, or ARF",
"       </td>",
"       <td>",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLE or scleroderma",
"       </td>",
"       <td>",
"        Raynaud phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Takayasu arteritis",
"       </td>",
"       <td>",
"        Absent pulses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"4\">",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        IBD, SLE, or vasculitis",
"       </td>",
"       <td>",
"        Weight loss or poor growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IBD",
"       </td>",
"       <td>",
"        Diarrhea and abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis",
"       </td>",
"       <td>",
"        Preceding infectious gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HSP",
"       </td>",
"       <td>",
"        Intermittent colicky abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"3\">",
"        Genitourinary",
"       </td>",
"       <td>",
"        Gonococcal arthritis",
"       </td>",
"       <td>",
"        Pustular urethritis or cervicitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis",
"       </td>",
"       <td>",
"        Non-gonococcal urethritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behcet disease or IBD",
"       </td>",
"       <td>",
"        Large painful genital ulcerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"3\">",
"        Hematologic",
"       </td>",
"       <td>",
"        SLE or hemoglobinopathy (eg, SCD)",
"       </td>",
"       <td>",
"        Hemolytic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLE",
"       </td>",
"       <td>",
"        Pancytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding disorders",
"       </td>",
"       <td>",
"        Hemarthrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"5\">",
"        Neurologic",
"       </td>",
"       <td>",
"        SLE",
"       </td>",
"       <td>",
"        Seizures and psychosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLE or fibromyalgia",
"       </td>",
"       <td>",
"        Difficulty concentrating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLE, vasculitis, or hypercoagulability",
"       </td>",
"       <td>",
"        Stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"       <td>",
"        Asymmetric polyneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatomyositis and polymyositis",
"       </td>",
"       <td>",
"        Proximal muscle weakness",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SLE: systemic lupus erythematous; JIA: juvenile&nbsp;idiopathic arthritis; ARF: acute rheumatic fever; IBD: inflammatory bowel disease; SCD: sickle cell disease.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Yukiko Kimura and TR Southwood.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25965=[""].join("\n");
var outline_f25_22_25965=null;
var title_f25_22_25966="AC-T for breast cancer";
var content_f25_22_25966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (T) chemotherapy for adjuvant treatment of breast cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: AC is given every 21 days for four cycles; paclitaxel is given every seven days of a 28 day cycle for three cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5 percent dextrose in water (D5W). The presence of local erythematous streaking along the vein as well as facial flushing may be signs that administration is too rapid. If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes. Rapid infusions may produce nasal burning or congestion that is relieved by slowing the rate.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        After completion of AC, administer:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        80 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS or D5W to a final concentration of 0.3 to 1.2 mg/mL and administer over one hour*.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally twelve and six hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration. Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Further information on infusion reactions, including management, is available. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Doxorubicin is a vesicant and can cause significant tissue damage if an extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. If extravasation occurs, apply ice to the site and consider use of dexrazoxane. Paclitaxel can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Not applicable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Dose adjustment is not necessary for doxorubicin or paclitaxel in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. For patients with preexisting hepatic impairment, dose adjustments in doxorubicin, cyclophosphamide, and paclitaxel may be needed. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        A baseline assessment of LVEF is recommended, with periodic reassessment of during therapy. The risk of doxorubicin-associated cardiac dysfunction is related to cumulative dose. The risk is increased in patients with underlying heart disease, when anthracyclines are used concurrently with other cardiotoxic agents or radiation, and in patients previously treated with mediastinal or chest wall irradiation. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin",
"        <sup>",
"         [2]",
"        </sup>",
"        . Further information on anthracycline-associated cardiotoxicity, including discussion about prevention and treatment, is available. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count every two weeks prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum electrolytes and liver and renal function tests every two weeks prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment cycle of paclitaxel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; During treatment with doxorubicin or paclitaxel, assess line site periodically during infusion of chemotherapy for signs and symptoms of extravasation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Subsequent cycles should be delayed until the absolute neutrophil count is greater than 1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count greater than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If there is more than a three week delay in treatment, a dose reduction of 25 percent is recommended",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        For patients who develop severe neuropathy (grade 3 or 4) that persists for a week or longer, the dose of paclitaxel should be reduced by 20 percent for subsequent courses of paclitaxel; hold if severe toxicity persists after dose reduction",
"        <sup>",
"         [4]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of non-platinum chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for hepatic or renal dysfunction:",
"        </strong>",
"        Guidelines for managing doxorubicin, cyclophosphamide, and paclitaxel in patients who have changes in kidney or liver function during therapy are addressed in detail separately. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count.",
"     <br/>",
"     * Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Sparano JA, et al. N Engl J Med 2008; 358:1663.",
"      </li>",
"      <li>",
"       Adriamycin (doxorubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).",
"      </li>",
"      <li>",
"       Taxol (paclitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25966=[""].join("\n");
var outline_f25_22_25966=null;
var title_f25_22_25967="Chest radiograph depicting a retrocardiac mass";
var content_f25_22_25967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph depicting a retrocardiac mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP view of the chest radiograph demonstrates a paraesophageal hernia identified as a retrocardiac mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Rosen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_22_25967=[""].join("\n");
var outline_f25_22_25967=null;
     